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1 Chapter I 
General introduction 
 
 
 
  
2 Chapter I  
 
1.1 Cancer - definition and significance 
The National Cancer Institute defines cancer as a “term used for diseases in which abnormal cells 
divide without control and are able to invade other tissues”. More than 100 different identified 
types of cancer underline the variability of this disease (c.f. 
http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer). Malignant neoplasms, 
termed cancer, differ from benign neoplasms in the ability to infiltrate the surrounding tissues, 
resulting in the destruction of the latter, as well as the ability to spread to regional lymph nodes 
and distant organs via blood vessels and lymphatic channels (metastasis). 
Cancer is among the leading causes of death worldwide, with estimated 8.2 million deaths in 2012 
[1] and additional 32.6 million people living with cancer. Among the multitude of different cancer 
types, lung (1.6 million), liver (0.75 million), stomach, colorectal (both 0.7 million) and breast 
cancers (0.5 million) cause the highest number of deaths each year. The frequency of cancer types 
and related deaths is sex-dependent, which becomes most obvious in the case of breast cancer 
which had the highest mortality among women in 2008 [2]. 
 
1.2 Classification of cancer 
The variety of cancer types can be described according to different criteria. Based on the cells of 
origin, cancer is usually distinguished in carcinomas, and sarcomas, the latter including 
hematological neoplasms (leukemia and lymphoma), all of which are divided into subgroups [3]. 
Carcinomas, which are divided into the major subtypes adenocarcinoma and squamous cell 
carcinoma, arise from epithelial cells and represent the vast majority of all cancer types (85 %), 
including most neoplasms of lung, breast, prostate, colon and pancreas. Sarcomas are defined as 
cancer arising from mesenchymal origin, e.g. bone, muscle or connective tissues. The 
hematological neoplasms leukemia and lymphoma arise from the hematopoietic tissue. Leukemia 
develops in the bone marrow and is characterized by an overproduction of immature white blood 
cells. Lymphomas (e. g. Hodgkin and non-Hodgkin lymphoma) and myelomas develop in the 
primary and secondary lymphatic tissues.  
 
1.3 Development of cancer 
Cancer development is most commonly regarded as a clonal process, derived from a single cell 
[4], comprising different stages, termed initiation, promotion and progression [5]. Initiation is 
characterized by alterations (mutations) in the genome, whereby additional spontaneous 
mutations and external effectors are considered as triggers. The external carcinogenic factors 
comprise physical (e.g. ionizing radiation), chemical (e.g. polycyclic aromatic hydrocarbons, 
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alkylating agents) and biological (e.g. viral infections [6]) damages. Epigenetic alterations such as 
changes in DNA methylation [7] as well as a variety of possible mutations, for example alterations 
in single nucleotides [8, 9] or chromosomal translocation [10-12], have been associated with 
cancer development.  
Especially mutations in tumor suppressor genes (usually accompanied by a loss of function) and 
proto-oncogenes (usually gain of function) are associated with cancer [13]. For instance, cells with 
mutations in the tumor suppressor gene p53, i.e. decrease/loss of function of the p53 protein, 
can escape apoptosis [14]. However, “Gain of function” such as enhanced cell proliferation or the 
stimulation of epithelial-to-mesenchymal transition, cell motility and invasion are associated with 
p53 mutations as well [14]. In contrast, mutated or abnormally expressed proto-oncogenes (then 
referred to as activated oncogenes) and the related oncoproteins (e.g. platelet derived growth 
factor, epidermal growth factor receptor) commonly trigger proliferation or restrict apoptosis 
[15]. Besides mutations in tumor suppressor or proto-oncogenes, mutations resulting in reduced 
DNA repair contribute to cancer development [16, 17].   
It is assumed that promoting agents (e.g. phorbol esters, reactive oxygen species [18-21]), acting 
as mitogens, trigger clonal expansion and proliferation of the initiated tumor cell [5, 22, 23]. The 
genetic instability, acquired during initiation, in combination with the proliferation and clonal 
expansion in the promotion phase leads to varying malignant phenotypes during the progression 
phase [24], a process which can take many years, increasing the heterogeneity of the developing 
tumor [5]. However, it should be noted that carcinogenesis is considered as a multicausal, 
multigenic and multistep process, involving genetic as well as epigenetic factors [25]. Besides 
spontaneous mutations and external factors, stromal cells, forming a permissive 
microenvironment (niche) surrounding the initiated cell, are assumed to contribute to 
carcinogenesis [26].  
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1.4 Tumor heterogeneity and cancer stem cells 
The phenotypic heterogeneity of cancer cells [27, 28] is not fully understood. Two models the 
“stochastic” and the “cancer stem cell model”, were proposed [29-31].  
The “classical” model assumes that random (stochastic) events change the behavior of single 
tumor cells, resulting in heterogeneity. These events can either be intrinsic (e.g. transcription 
factors) or extrinsic (e.g. microenvironment, immune response). In this model, all cancer cells 
have the potential of self-renewal and proliferation. 
In contrast, the stem cell model assumes the similarity of tumors to healthy tissues (e.g. colon 
epithelium and blood cells), which are commonly organized in hierarchies with stem cells, 
possessing self-renewing capacity, on top. In this model, so-called cancer stem cells give rise to 
progenitor cells, which in turn differentiate or proliferate resulting in heterogeneous populations 
of cancer cells.  
However, high plasticity (ability to change the phenotype) between different “states” of cancer 
cells was recently reported for breast cancer. Sorted cells of three distinct differentiation states, 
described as stem-like (CD24-/CD44high/EpCAMlow), basal (CD24-/CD44high/EpCAM-) and luminal 
(CD24high/CD44low/EpCAMhigh), were able to give rise to all three phenotypes by interconversion,   
resulting in initial equilibrium proportions [32]. It has to be stated that the authors of the cited 
study did not claim that their data would contradict the presence of “cancer stem cells”. In 
contrast, they concluded that cells in different “states” are able to give rise to “cancer stem cells”. 
The increasing knowledge about plasticity of cancer cells challenges cancer hierarchy, requiring 
more complex models to explain cancer cell heterogeneity. One approach, addressing this issue 
is for example the “CSC plasticity model” [33], which considers the majority of the tumor cell mass 
as cells with stem cell properties. The stem cell properties are supposed to vary depending, for 
example, on the microenvironment.  
 
1.4.1 Cancer stem cells or cancer initiating cells? 
Uni- or multipotent adult stem cells in healthy tissues share properties with cancer cells, such as 
self-renewal and asymmetric division, giving rise to new tissue [34]. This fueled speculations 
about the existence of cancer stem cells (CSC) and their involvement in carcinogenesis and 
relapse. The self-renewing capacity of both cell types is considered to be regulated by similar 
signaling pathways (e.g. Wnt [35, 36], Sonic Hedgehog [36, 37] and Notch [38, 39]). According to 
McCulloch and Siminovitch [40, 41], the proof of stem cell properties is achieved by 
demonstrating the self-renewing capacity, illustrated by colony forming ability in vitro [42] and 
tumorigenicity in vivo. Lapidot et al. identified “cancer stem cells” in acute myeloid leukemia 
(AML) [43], and suggested the formation of colonies or tumor spheres in vitro [44, 45] and the 
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tumorigenicity in immunodeficient mice as the state-of-the-art methods to define “cancer stem 
cell” properties [29, 46]. In accordance to the methods used for the actual proof of stem cell-like 
properties by tumor initiation respectively sphere formation, Beck et al. suggested the use of the 
terms “tumor propagating” or “cancer initiating cell” (TPC, CIC) rather than cancer stem cell [29].  
Apart from self-renewal and asymmetric cell division, adult stem cells and CICs share 
characteristics such as the ability to secrete growth factors, leading to independent growth 
control of cells and induction of angiogenesis  [47], the expression of ABC transporters [29] and 
other cell surface proteins referred to as stem cell markers (discussed in section 1.4.3). 
 
1.4.2 Origin of cancer initiating cells 
The origin of CICs has not unambiguously been clarified. Different hypotheses especially for 
hematological diseases, have been discussed in the last years [43]. CICs may result from 
transforming mutations of adult stem cells leading to abnormal growth and differentiation [34, 
48-50]. This is supported by the fact that tissue specific stem cell markers are also expressed on 
the corresponding CICs [51]. The influence of the surrounding microenvironment (niche), 
especially in endothelial tissue, may also play a crucial role in the development of CICs originating 
from adult stem cells [47, 52, 53].  
A different concept considers mutations in progenitor cells as initial step in the development of 
CICs [34, 54], since only few mutations affecting mechanisms which regulate cell death would be 
necessary to gain stem cell properties accompanied by uncontrolled cell growth [43, 55, 56]. 
Additionally, de-differentiation of progenitor or differentiated cells as well as the fusion of tissue-
specific stem cells with circulating bone marrow stem cells are discussed [51, 57].  
 
1.4.3 Identification of cancer initiating cells 
A considerable number of markers, usually expressed on CICs and adult stem cells originating 
from specific tissues, was described in the last years. The detection of their expression is the most 
commonly used method for the identification of CICs [46]. To name only a few examples, the 
detection of CD133 [58, 59] respectively a combination of CD133 and nestin [60, 61] is considered 
indicative for brain tumor initiating cells (BTIC). The identification of breast cancer initiating cells 
(BCIC) is usually based on the differential expression of the cell surface proteins CD24 and CD44. 
The expression pattern of BCIC populations was reported as CD24-/CD44+ [62-64]. Nevertheless, 
there is no clear correlation between the expression of these proteins and stem cell properties 
(c.f. section 1.4.1) [65].    
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Besides the detection of cell surface proteins, the identification of CICs based on functional assays 
was proposed, e. g. by determining the activities of aldehyde dehydrogenase (ALDH) [66-68] or 
the proteasome [69]. 
Especially in the absence of other specific markers, the determination of so-called side 
populations (SP), expressing ATP-binding cassette (ABC) transporters such as ABCB1, ABCC1 and 
ABCG2 may be a valuable approach to the identification and enrichment of CICs [70]. However, 
the expression of such transporters alone is not strictly associated with stem cell properties, since 
CICs often represent only a fraction of the side population [71, 72]. In addition to the 
Hoechst 33342 efflux assay for the identification of SPs [73, 74], methods such as the ABCG2-
mediated mitoxantrone efflux assay [75] or the immunodetection of transporter proteins are 
frequently performed. Apart from being considered as marker proteins, ABC-transporters such as 
ABCB1 (P-gp) [76] and ABCG2 [77-79] impart increased resistance against chemotherapy, as a 
considerable number of cytostatic drugs are substrates of these efflux pumps [80].  
Commercially available antibodies against CIC markers in combination with flow cytometry led to 
the identification of CICs in a great variety of cancer types, including brain tumors [44, 58], breast 
cancer [62], colorectal cancer [81, 82], skin squamous cell carcinoma [83], head and neck cancer 
[84], lung cancer [85], pancreatic cancer [86], prostate cancer[87] and ovarian cancer [88, 89].   
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1.5 Cancer chemotherapy 
Chemotherapeutic regimens for the treatment of the majority of cancer types comprise a 
combination of different drugs. It is conceivable that enhanced anti-cancer efficacy of drug 
combinations is accompanied by reduced systemic toxicity, since lower doses of the individual 
drugs are required, especially, if the mechanisms of action and the side effects of the individual 
drugs do not overlap. Profound knowledge of the phenotype (e.g. expression of HER2 or EGFR) or 
resistance mechanisms (e.g. increased expression of dihydrofolate reductase in case of 
methotrexate treatment) favors the identification of appropriate drug combinations. Most 
chemotherapeutic regimens are applied in repetitive cycles in order to achieve a reduction of 
tumor mass in each cycle [90].  
 
1.5.1 Alkylating agents  
Despite the development of targeted anti-tumor drugs, alkylating agents continue to play a 
central role amongst cytotoxic chemotherapeutics (e.g. antifolates, antimetabolites, antimitotics, 
platinum analogs, topoisomerase inhibitors). Such drugs are applied in conventional combination 
therapy as well as in high-dose protocols with subsequent hematopoietic cell transplantation 
[91]. Besides the classical alkylating agents (which will be discussed in the following), so-called 
nonclassical agents, which do not contain alkylating moieties such as the nitrosourea or the 
nitrogen mustard group are frequently used (e.g. procarbazine, temozolomide). These 
“monofunctional” drugs are cytotoxic due to covalent binding to the DNA, too, but they usually 
undergo complex metabolic transformation to active intermediates [91]. 
 
1.5.2 Classical alkylating agents 
Alkyl alkanesulfonates (e.g. busulfan), nitrosureas (e.g. carmustine) and nitrogen mustard 
derivatives (e.g. bendamustine), the first non-hormonal anti-cancer drugs, are usually classified 
as classical alkylating agents. The primary mechanism of action is the covalent binding to DNA, 
whereby an active intermediate acts as alkylating agent rather than the parent compound. The 
alkylating reaction may proceed according to a SN1 (e.g. chloroethylnitrosureas) or SN2 (e.g. 
busulfan) mechanism, which particularly differ regarding the rate of reaction. Alkylation of DNA 
results in cytotoxic, mutagenic and carcinogenic effects. The effectiveness of alkylating agents can 
be enhanced, for example, by radiation, hyperthermia, inhibition of DNA repair mechanisms and 
glutathione depletion [91]. The examination of the sites of alkylation revealed that oxygen atoms 
in phosphates [92, 93] and bases as well as nitrogen atoms of purine bases [94] are preferentially 
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alkylated. However, DNA is not exclusively alkylated, but other cellular constituents such as 
proteins are alkylated to a minor extent, as shown for nitrogen mustard [95].  
Bifunctional alkylators (e.g. nitrogen mustard derivatives) cause intra- and, in particular, 
interstrand crosslinks, responsible for effective inhibition of DNA replication and transcription 
[96, 97]. This is reflected by overall higher cytotoxic activities of bifunctional agents [98, 99]. 
Apart from different reactivity of the alkylating moiety, the antitumor activities of alkylating 
agents mainly depend on their (physico)chemical properties, influencing the pharmacokinetics 
including diffusion or transport across membranes or the activation of cellular resistance 
mechanisms [91]. For instance, the uptake of melphalan was reported to be enhanced by amino 
acid transporters [100] and the human organic cation transporter 3 (OCT3) [101], which was 
recently identified in some human cancer cell lines [101, 102]. Contrary, reduced drug uptake is 
a well-known resistance mechanism, for example, for melphalan [103] and mustine (nitrogen 
mustard) [104]. Further resistance mechanisms against alkylating agents include enhanced drug 
inactivation, changes in cell-cycle checkpoint function (e.g. loss of normal p53 function) and 
alterations in DNA repair mechanisms (e.g. enhanced  base – and nucleotide excision repair)  [91]. 
The induction of such resistance mechanisms is often accompanied by the development of cross-
resistances against other alkylating agents [91]. 
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1.5.2.1 Nitrogen mustard (N-Lost) derivatives 
The term “Lost” for bis(2-chloroethyl) derivatives of nitrogen and sulfur goes back to the names 
of the inventors of this compound class, Lommel and Steinkopf. S-Lost (sulfur mustard, yellow 
cross) (Fig. 1.1) was used as a warfare gas in World War I. Massive lymphopenia, 
granulocytopenia, thrombocytopenia and moderate anemia in soldiers, who were accidentally 
exposed to S-Lost, suggested the therapeutic potential of Lost derivatives  [105].  
 
 
Figure 1.1: Structures of sulfur mustard (war gas), nitrogen mustard (N-Lost, mustine, 
chlormethine, mechlorethamine) and various derivatives. 
 
Based on these findings, clinical trials on the effects of mustard derivatives against neoplasms of 
lymphoid tissue were performed in the US. Sulfur mustard derivatives proved to be inappropriate 
for parenteral administration due to severe adverse effects [105]. By contrast, the less reactive 
nitrogen mustard derivatives (e.g. mustine (mechlorethamine); c.f. Fig. 1.1) were better tolerated 
and led to an initial remission, especially in Hodgkin´s lymphoma [106, 107].  
Subsequent investigations focused on structural modification of the N-Lost structure, aiming at 
higher chemical stability and less side effects. Therefore, the methyl group in mustine was 
replaced by electron-withdrawing substituents, rendering the nitrogen less nucleophilic (Fig. 1.1). 
Indeed, such N-Lost derivatives revealed lower systemic toxicities, though accompanied by 
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reduced antitumor activity. Melphalan, chlorambucil, bendamustine, cyclophosphamide and 
ifosfamide are examples of approved nitrogen mustard derivatives (c.f. Fig. 1.1). The aziridine 
derivative thio-TEPA is also related to the class of nitrogen mustards, although it does not 
comprise the bis(2-chloroethyl) group. Upon protonation, the aziridine rings correspond to 
aziridinium ions, reminiscent of the highly reactive alkylating intermediates formed from N-Lost 
derived alkylators. 
Most nitrogen mustard derivatives are indicated to treat hematologic malignancies such as 
chronic lymphocytic leukemia (CLL) [108-110], non-Hodgkin´s lymphoma (NHL) [111, 112] and 
multiple myeloma (MM) [113]. In contrast to classical mustard derivatives such as melphalan, 
spontaneous formation of aziridinium intermediates does not occur in case of cyclophosphamide 
and analogs such as ifosfamide. Instead, metabolic activation by CYP450 enzymes is required 
[114]. Cyclophosphamide and ifosfamide are also used in the treatment of solid tumors (e.g. 
breast cancer [115]; soft tissue sarcoma [116]). 
The high alkylating potency of the N-Lost moiety is based on the presence of a nucleophilic center 
(S or N) in -position relative to the halogen atom, enabling an intramolecular nucleophilic attack 
of a lone pair of electrons. This results in the displacement of the chloro substituent and the 
formation of a positively charged group, the highly reactive electrophilic aziridinium moiety, 
which subsequently reacts with nucleophiles in the DNA (Fig. 1.2). Due to the bifunctional 
character of the nitrogen mustard, this reaction can take place twice, resulting in DNA cross-links 
[105].  
 
Figure 1.2: Mechanism of the alkylation of nucleophiles (Nu) by nitrogen mustard derivatives. The 
bifunctional character enables two consecutive alkylating steps.  
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1.6 Bendamustine 
1.6.1 Development of bendamustine 
Bendamustine (initially termed IMET3393) (c.f. Fig. 1.1) was synthesized in 1963 by Ozegowski et 
al. at the Institute for Microbiology and Experimental Therapy (IMET) in Jena [117, 118]. The 
inventors aimed at combining the alkylating activity of the nitrogen mustard group and potential 
antimetabolite properties of the benzimidazole scaffold. In addition, the electron-withdrawing 
benzimidazole structure should decrease the nucleophilicity of the nitrogen atom in the N-Lost 
group resulting in decreased reactivity and reduced toxicity [119]. To improve the solubility of the 
new compound, the butyric acid side chain was introduced, by analogy with the approach known 
from chlorambucil (c.f. Fig. 1.1).   
First clinical trials with bendamustine in the treatment of several cancer types (e.g., hematologic 
malignancies, breast cancer, small cell lung cancer, ovarial cancer) were performed in 1965 [119]. 
However, bendamustine was barely used in Europe and the US before the end of the “cold war”. 
Subsequently, the drug was “re-discovered”, came into the focus of cancer research in Europe 
and the US at the end of the 1990s, and has been investigated in many clinical trials.  
 
1.6.2 Bendamustine in cancer therapy 
Bendamustine is approved for the treatment of CLL [110, 120], indolent NHL [121] and MM [122, 
123] in Germany (Levact®) and for CLL and indolent NHL in the US (Treanda®). Most treatment 
regimens apply bendamustine in combination with other cytostatic drugs [124], often with 
rituximab [125-127]. Clinical research on bendamustine has been intensified in the last years. 
However, most trials with bendamustine as a single agent, for instance, for the treatment of bile 
duct cancer [128], soft tissue sarcoma [129], germ cell cancer [130], small cell lung cancer [131-
133], pretreated metastatic [134, 135] or advanced [136] breast cancer revealed on the one hand 
good tolerability, but on the other hand limited benefit. Studies on bendamustine in combination 
therapy, for example with methotrexate and 5-fluorouracil for the treatment of metastatic breast 
cancer [137] or bendamustine with carboplatin for the treatment of small cell lung cancer [138], 
reported efficacies which were comparable to respective standard treatment regimens. Due to 
mild side effects and reduced cross resistances with other alkylating drugs, bendamustine was 
claimed to be an interesting drug for the treatment of patients in poor clinical condition [139] or 
as second line therapy [111, 140, 141].  
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1.6.3 Mechanism of action  
Speculations about mechanisms of action of bendamustine different from the alkylation of DNA 
go back to the synthesis of the compound, based on the idea that the benzimidazole scaffold 
might confer antimetabolite activities. This was supported by the COMPARE analysis conducted 
at the national cancer institute [142]. In this study, bendamustine revealed a unique activity 
pattern against human cancer cell lines, which differed significantly from the activity pattern of 
other nitrogen mustard derivatives such as melphalan, chlorambucil and cyclophosphamide. 
Gene expression analyses indicated differential bendamustine-induced effects with respect to 
genes grouped into “response to DNA-damage stress” and “DNA-metabolism”. These findings led 
the authors to the assumption that bendamustine is unique in its ability to induce p53, regulate 
DNA-repair and inhibit mitotic checkpoints, leading to mitotic catastrophe [142]. However, 
detailed experiments verifying these mechanisms are lacking.  
Several recent publications reported the induction of p53 [143, 144] and a concentration 
dependent induction of G2 phase arrest by bendamustine [143, 145, 146]. Additional evidence 
for effects on the cell cycle was provided by the analysis of proteins regulating cell cycle 
checkpoints, e. g. Chk1 [145] and Chk2 [143], and the induction of proteins involved in apoptosis 
(caspase-2 and caspase-8) [146]. Therefore, the induction of mitotic catastrophe, an alternate 
mechanism of cell death, which is particularly important in cells resistant to apoptosis, is 
discussed for bendamustine [146]. 
Recently, the putative activity as an antimetabolite was re-considered due to additive effects of 
various alkylating agents with bendamustine in vitro [147]. The fact that bendamustine was 
effective (e.g. induction of apoptosis) already after short exposure (3 hours), was interpreted as 
a hint to fast cellular uptake. Accordingly, the additive effect with other alkylating agents was 
explained by early effects of bendamustine combined with delayed cytotoxic effects of 
compounds entering the cells less rapidly. Moreover, co-incubation of bendamustine with 
cytosine arabinoside (CA) (pyrimidine antimetabolite) induced effects which are usually observed 
for combinations of pyrimidine with purine analogs (up-regulation of ENT1 expression and 
increased concentration of the active metabolite of CA, Ara-CTP). This was interpreted as further 
evidence for antimetabolite activity. 
 
1.6.4 Stability and metabolism 
The nitrogen mustard group is prone to chemical hydrolysis, in particular at neutral or basic pH 
values [148], resulting in the inactive bis(2-hydroxyethylamino)-substituted benzimidazole 
derivative upon twofold hydrolysis (Fig. 1.3). The hydrolytic decomposition is prevented or 
reduced at acidic pH, because the protonation of the nitrogen atom leads to decreased 
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nucleophilicity and, consequently, the tendency to form an aziridinium ion is considerably 
lowered. The hydrolysis rate is also retarded in the presence of high concentrations of chloride 
[148].   
 
 
Figure 1.3: Phase I metabolism and chemical hydrolysis of bendamustine. 
 
In addition to the chemical hydrolysis of the nitrogen mustard group in plasma, phase I and phase 
II metabolites of bendamustine are described in literature. Especially CYP1A2 was assumed to be 
relevant for the formation of the two known active phase I metabolites, N-desmethyl-
bendamustine and γ-OH-bendamustine (c.f. Fig. 1.3) [149]. With regard to phase II metabolites, 
biliary excretion of N-acetyl-L-cysteine conjugates was previously described as a mechanism of 
bendamustine elimination [150, 151].   
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2.1 Investigation of ABC transporter expression and cancer initiating cells 
in human cancer cell lines 
The expression of ATP driven efflux pumps (ABC transporters) such as ABCB1 and ABCG2 is known 
to confer resistance to diverse cytostatic drugs [1]. The exposure of cancer cells to cytostatic drugs 
such as topotecan can cause elevated ABCG2-expression [2]. Moreover, side populations of 
cancer cells, expressing ABC-transporters (ABCB1, ABCG2) were recently reported to comprise 
cancer initiating cells [3]. However, knowledge whether the expression of ABC-transporters is 
actually linked to properties of cancer initiating cells such as in vitro clonogenicity and 
tumorigenicity is incomplete. 
Aim of this project was the flow cytometric screening for cancer initiating- and side population 
cells in human brain tumor and breast cancer cells. Additionally, MCF-7 breast cancer cells were 
chosen for treatment with topotecan to examine the impact of this treatment on the expression 
of ABC-transporters and different marker proteins, which are commonly used for the 
identification of breast cancer initiating cells (CD24, CD44, EpCAM). Moreover, the effect of 
topotecan treatment on the in vitro clonogenicity and the tumorigencity of MCF-7 cells was 
planned to be investigated.  
 
2.2 Investigations on the stability and cytotoxic activity of bendamustine 
esters 
Aiming at oral bioavailability, improved pharmacokinetic properties or increased stability, various 
bendamustine esters [4], oligomers [5] and complex pharmaceutical formulations [6] were 
claimed for patent in the last years. Among the recently reported bendamustine derivatives are 
a number of neutral and basic esters. Such structural modifications may not only influence the 
stability of the nitrogen mustard group, but also the cytotoxic activity. Moreover, in a biological 
environment the spectrum of possible degradation products for bendamustine esters is expected 
to become more complex compared to the parent compound, as, in addition to nucleophiles 
attacking the nitrogen mustard moiety, enzymatic process such as oxidation and, in particular, 
hydrolysis may contribute to degradation.  
The second objective of this project was to establish and apply analytical procedures for the 
detailed investigation of the degradation of structurally diverse bendamustine esters in aqueous 
solution as well as in murine and human plasma. Moreover, as these esters might act not only as 
bendamustine prodrugs but also as cytotoxic agents of their own, investigations on the 
antiproliferative activity at a broad panel of human cancer cell lines, including hematologic 
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malignancies, osteosarcomas and different carcinomas, were envisaged. In addition, studies on 
the cellular uptake of representative esters and the parent compound as well as the effect on the 
expression of the p53 tumor suppressor were planned in case of eventually discovered significant 
differences in cytotoxicity. 
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3.1 Introduction 
The expression of ATP-driven efflux transporters such as the breast cancer resistance protein 
(BCRP, ABCG2) is a crucial mechanism that causes multidrug resistance in cancer cells [1]. 
Determining the efflux of different substrates, e.g. the fluorescent Hoechst dye [2] or 
mitoxantrone [3] allows to identify cancer cells expressing ABCG2, whereas Hoechst efflux defines 
so-called side populations [4]. Presupposed that resistance against cytostatics is also a property 
of cancer initiating cells (CICs), side populations are often considered to comprise an increased 
fraction of those cells compared to the bulk of cancer cells. Exposing cancer cells in vitro to 
cytostatic drugs like topotecan, mitoxantrone [5], and doxorubicin [6] can cause elevated ABCG2 
expression. The effect of such cytotoxic treatments on the regulation and expression of other 
proteins related to poor clinical outcome has been less extensively examined. 
Brain tumor initiating cells were previously described as a CD133+ subpopulation [7] and identified 
in different brain tumor types. Nowadays, CD133 is frequently used as a marker for cancer 
initiating cells originating from diverse tumor entities, for example, ovarian and liver cancer [8, 
9]. However, the function of CD133, which was first described as a marker of primitive 
hematopoietic and neural stem cells [10], is not completely clarified.  
Treatment efficiency and outcome of breast cancer patients is strongly affected by tumor 
heterogeneity, which therefore, constitutes a significant clinical problem. Nowadays the human 
epidermal growth factor receptor 2 (HER2) and the estrogen receptor (ER) represent well-
established diagnostic markers and therapeutic drug targets whereas the importance of CD24, 
CD44 and EpCAM is less clear. Distinct expression profiles of these proteins are considered as 
markers of CICs and their expression has been related to mechanisms involved in metastasis and 
therefore with poor clinical outcome. Among other markers, the expression profile of a CIC  
(sub-)population in breast cancer has been described as CD24-/low/CD44+ [11].  
Considering the fact that increased CD24 expression is linked to poor prognosis in different solid 
tumor types including breast cancer [12, 13], low CD24 expression in CICs appears inexplicable at 
first glance. However, the association of high CD24 expression levels and metastasis [14], 
enhanced cell proliferation [15] and in vitro clonogenicity [16] is widely accepted. Nevertheless, 
regulation and function of CD24 are not fully elucidated yet. 
The CD44 molecule, respectively variants thereof [17], is almost ubiquitously expressed on 
carcinoma cells [18]. It can interact with a variety of effectors [19, 20] and is involved in a 
multitude of regulatory mechanisms related to adhesion, cell proliferation, migration, 
invasiveness and chemoresistance [18, 21, 22].  
Likewise, EpCAM, which was first described as a marker of human embryonic stem cells, is 
expressed on cancer cells of a variety of entities [23]. In many cancer types, including breast 
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cancer, high expression levels of EpCAM correlate with poor prognosis [24]. Although the 
functions of EpCAM as a cell adhesion molecule and promoter of cell proliferation are generally 
accepted and alterations in the expression level are closely related to epithelial-mesenchymal 
transition (EMT) during metastasis, the role of EpCAM in cancer cells is not yet fully elucidated 
[23, 25].  
The HER2 receptor is overexpressed in up to 20 to 25 % of invasive breast cancers [26] and 
predicts poor clinical outcome. HER2 overexpression can result in constitutive kinase activity that 
causes increased cell proliferation and invasion [27]. 
In order to investigate correlations between side populations and cancer initiating cells, a panel 
of human brain tumor and breast cancer cell lines was screened for the expression of different 
CIC markers (CD133, CD24, CD44) as well as ABCB1 and ABCG2. Moreover, it was explored 
whether the topotecan induced ABCG2 expression manipulates the CD24, CD44, EpCAM, and 
HER2 related phenotype and if an enhanced ABCG2 expression affects in vitro clonogenicity or 
tumorigenicity in immunodeficient mice. To this end, ABCG2 expression was induced in MCF-7 
breast cancer cells by long-term exposure to topotecan and the respective biomarker expression 
was assessed by flow cytometry. Moreover, the impact of topotecan treatment on cell 
propagation and the capacity of self-renewal was explored in mammosphere formation assays 
and the tumorigenicity of untreated vs. topotecan treated cells was evaluated in immunodeficient 
mice.  
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3.2 Materials and methods 
3.2.1 Reagents and antibodies 
Unless stated otherwise, all commercially available solvents and chemicals were of analytical 
grade and purchased from Merck (Darmstadt, Germany) or Sigma (Taufkirchen, Germany). For 
the purification of demineralized water, a Milli-Q system (Millipore, Eschborn, Germany) was 
used. A 1 mM stock solution of mitoxantrone was prepared by diluting Novatron® (Wyeth 
Pharma, Münster, Germany) in 70 % ethanol. Doxorubicin and topotecan were both from Sigma 
(Taufkirchen, Germany) and the stock solutions were also prepared in 70 % ethanol. Tariquidar 
was synthesized in our laboratory according to literature [28, 29] and dissolved in 70 % ethanol 
(100 µM). Calcein-AM (100 µM), 5-fluorouracil, methotrexate (all purchased from Sigma, 
Taufkirchen, Germany) and fumitremorgin C (1 mM) (Merck, Darmstadt, Germany) were 
dissolved in DMSO. All stock solutions were stored at – 20 °C. A solution of 2 % glutardialdehyde 
(v/v) in PBS was prepared by diluting the commercially available 25 % (v/v) solution (Sigma, 
Taufkirchen, Germany). PBS containing 2 % fetal calf serum (FCS; Biochrom, Berlin, Germany) was 
used as buffer for all cytometric measurements. The following antibodies were used for the flow 
cytometric analyses: APC anti-mouse/human CD44, Alexa Fluor 488 anti-mouse/human CD44, 
FITC anti-human CD24, Alexa Fluor 647 anti-human CD24, Brilliant Violet 421 anti-human CD326 
(EpCAM) and pacific blue anti-human CD338 (ABCG2), as well as the isotype controls 
recommended by the manufacturer were purchased from BioLegend (London, UK). FITC anti-
human P-glycoprotein and IgG2b isotype control as well as Anti-Her-2/neu PE respectively PE 
Mouse IgG1 Isotype control were from BD Biosciences (Heidelberg, Germany). CD133/1-PE (clone 
AC133) respectively CD133/1-APC (clone AC133) antibodies and the respective mouse IgG1 
isotype controls were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). 
 
3.2.2 Cell lines and standard cell culture 
The human brain tumor cell lines LN-18 (ATCC® CRL-2610™; glioblastoma grade IV), U-87 MG 
(ATCC® HTB-14™; astrocytoma grad IV), SW-1783 (ATCC® HTB-13; astrocytoma grade III) and Daoy 
(ATCC® HTB-186™; desmoplastic cerebellar medulloblastoma) as well as the human breast cancer 
cell lines MCF-7 (ATCC® HTB-22™; breast adenocarcinoma), ZR-75-1 (ATCC® CRL-1500™; breast 
ductal carcinoma), T-47D (ATCC® HTB-133™; mammary gland ductal carcinoma), JIMT-1 (provided 
by Prof. Dr. Gero Brockhoff, Institute of Gynecology and Obstetrics, University of Regensburg), 
MDA-MB-231 (ATCC® HTB-26™; triple negative breast adenocarcinoma), HCC-1806 (triple 
negative primary acantholytic squamous cell carcinoma) and HCC-1937 (triple negative primary 
ductal carcinoma) (both provided by Dr. Jörg Engel, Frauenklinik, University of Würzburg) were 
maintained in RPMI-1640 (Sigma, Taufkirchen, Germany), supplemented with 2 g/L NaHCO3 
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(Merck, Darmstadt, Germany), 110 mg/L sodium pyruvate, 10 mM HEPES (both from Serva, 
Heidelberg, Germany) and 10 % fetal calf serum (Biochrom, Berlin, Germany). For the incubation 
of MCF-7/Topo cells (ABCG2 overexpressing subclone of MCF-7) [29, 30] the culture medium was 
additionally supplemented with 500 nM topotecan. For experiments determining the expression 
stability of ABCG2 in MCF-7/Topo cells, the cells (hereafter referred to as MCF-7/Topo/wo) were 
maintained for several weeks in topotecan-free medium.All cell lines were maintained in cell 
culture flasks (Sarsted, Nurembrecht, Germany) at 37 °C and 5 % CO2 in a water-saturated 
atmosphere and serially passaged as required following the treatment with trypsin/EDTA (0.5 
mg/mL / 0.22 mg/mL) (PAA, Pasching, Austria). 
 
3.2.3 Neuro-/mammosphere culture and limiting dilution assay 
Neuro- respectively mammosphere culture was basically performed as previously described [31-
33]. Cells were maintained in suspension culture, using ultra-low attachment plates (Corning Inc., 
Corning, NY). MCF-7, MCF-7/Topo and MCF-7/Topo-CD24low cells were maintained in DMEM/F12 
supplemented with 20 ng/mL bFGF (both from Gibco®/Life Technologies, Carlsbad, CA), 20 ng/mL 
EGF and 5 µg/mL insulin (both from Sigma, Taufkirchen, Germany). For the incubation of Daoy 
and sorted CD133+-Daoy cells, the medium described above was additionally supplemented with 
B-27 (Gibco®/Life Technologies).  
The growth capacity was determined by serial passaging of MCF-7, MCF-7/Topo, sorted MCF-7-
CD24low, Daoy and sorted Daoy-CD133+ cells. To this end, 5 x 103 single cells were seeded per well 
in 100 µL medium. Every 3-4 days, fresh medium was added or, if the cells had reached confluency 
of approximately 80 %, spheres were enzymatically singularized and single cells were passaged. 
The cell growth was regularly monitored for at least 3 weeks. The expression of CD133 in sorted 
Daoy-CD133+ cells was again examined by flow cytometry (see 3.2.4.1) after 2 weeks of 
incubation. 
The mammo- respectively neurosphere forming ability of freshly sorted MCF-7/Topo-CD24low, 
and Daoy-CD133+ cells, was compared to unsorted cells using limiting dilution assays. For this 
purpose, different cell counts (1, 3, 10, 30, 100, 300, 1000 cells/well, 100µL) of singularized cells 
were plated in sextuplicate into 96-well ultra-low attachment plates (Corning). Wild type cells 
were trypsinized, washed 3 times with PBS in order to remove remaining FCS and trypsin and 
filtrated through a 40 µm cell strainer (BD Falcon, Heidelberg, Germany) to exclude agglomerates. 
Every 2-3 days, 20 µL of fresh medium were added and the number of spheres with diameters 
above 80 µm was determined in each well after 12 days [34, 35]. Pictures were taken with a DCM-
510 ocular microscope camera (OCS.tec GmbH & Co. KG, Erding, Germany) controlled by 
ScopePhoto V3.0.12.498 software (Hangzhou Scopetek Opto-electric Co., Ltd., Hangzhou, China). 
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3.2.4 Determination of IC50 values  
The IC50 values of 5-fluorouracil (5-FU), doxorubicin (Doxo) and methotrexate (MTX) on MCF-7 
and MCF-7/Topo cells were determined after 72 hours of incubation according to the procedure 
described in section 5.2.4. 
 
3.2.5 Flow cytometric screening of CIC - and side population markers  
3.2.5.1 Cell surface markers  
For the screening of cancer initiating cell-, respectively side population markers, cells in the log 
growth phase were detached by trypsinization. Prior to adjusting the cell number to 1 x 106 
cells/mL in PBS/FCS (PBS + 2 % FCS), the cells were washed twice with PBS. Subsequently, the 
samples were probed with different antibodies, depending on the tumor entity of the particular 
cell line. Brain tumor cells were analyzed for the expression of CD133, ABCB1 and ABCG2. The 
expression of CD24, CD44, ABCB1 and ABCG2 was determined for all human breast cancer cell 
lines described in section 3.2.2. Additionally, MCF-7 and MCF-7/Topo cells were analyzed for the 
expression of EpCAM and HER2. All antibodies were used in the dilution recommended by the 
manufacturer. The staining procedure was conducted analogous for all used antibodies and the 
corresponding isotype controls. After incubating the cells with the respective antibody for 30 
minutes on ice in the dark, they were washed with 800 µL ice-cold PBS/FCS, resuspended in 300 
µL of the latter and stored on ice in the dark until just before the measurements at a FACSCalibur™ 
respectively a FACSCanto™ II cytometer (both BD Biosciences, Heidelberg, Germany). For the 
different fluorochromes, the appropriate excitation lasers (pacific blue, brilliant-violet 421: 405 
nm (FACSCanto™ II); FITC, PE, alexa fluor 488: 488 nm; APC, alexa fluor 647: 635 nm) and emission 
filters (pacific blue,: 450/50 BP; brilliant-violet 421: 440/40 BP; alexa fluor 647: 670/20 BP (all 
FACSCanto™ II); FITC, alexa fluor 488: 530/30 BP; PE: 670 LP; APC: 661/16 BP) were selected, and 
photomultiplier voltages were adjusted on the autofluorescence of unstained cells. The 
discrimination of debris and cell agglomerates was performed by forward (FSC) and side scatter 
(SSC) gating. For reasons of significance, a suitable number of viable single cells (at least 2 x 105) 
was collected to distinguish rare events. Each experiment was performed at least twice. Data 
analysis was carried out with FlowJo V10 software (Treestar Inc., Ashland, OR). Viable single cells 
were gated according to forward and side scatter gates. The expression levels were reported as 
mean fluorescence intensity, respectively the percentage of cells, revealing a specific property, 
referred to living single cells. 
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3.2.5.2 Flow cytometric mitoxantrone efflux assay 
The investigation of ABCG2-activity was based on the previously described mitoxantrone efflux 
assay with minor alterations [3, 36]. In principle, unstained control cells, cells incubated with the 
fluorescent substrate mitoxantrone, and cells incubated with mitoxantrone and the ABCG2 
inhibitor fumitremorgin C (FTC) were compared for each tested cell line. 
Cells (approx. 80 % confluence) were detached by trypsinization, washed two times with PBS and 
resuspended in PBS containing 2 % FCS (PBS/FCS). For each sample, the cell number was adjusted 
to 5 x 105 cells per 500 µL and 2.5 µL mitoxantrone (1 mM stock solution in 70 % ethanol) were 
added to reach a final concentration of 5 µM. Subsequently, 5 µL of the 1 mM FTC stock solution 
(final concentration 10 µM), respectively an equivalent amount of solvent (DMSO) was added. 
The samples were vortexed and incubated at 37 °C for 30 minutes to allow maximal mitoxantrone 
uptake. After adding 800 µL cold PBS/FCS (4 °C) and centrifugation (3 minutes, 300 g, 4 °C), the 
cell pellet was resuspended in 300 µL PBS/FCS and stored on ice in the dark until just before 
measurement. Mitoxantrone accumulation respectively efflux was determined at a FACSCalibur™ 
(BD Biosciences, Heidelberg, Germany), using an excitation wavelength of 635 nm while emission 
was detected at 661/16 nm bandpass filter (FL4). A minimum of 2 x 105 viable single cells, defined 
by side scatter (SSC) and forward scatter (FSC) gates, were collected and raw data was analyzed 
with FlowJo V10 software.  
 
3.2.6 Fluorescence activated cell sorting (FACS)  
Tumor cells displaying marker expression patterns of interest, such as CD133+ in the case of Daoy 
cells and CD24low for MCF-7/Topo cells, were sorted using a FACSAria™ IIu (BD Biosciences, 
Heidelberg, Germany) equipped with a 70 µm nozzle. Except for small alterations in the antibody 
dilution, the staining procedure was performed exactly as described under 3.2.5.1 except for the 
omission of isotype controls. In brief: for Daoy, approximately 5 x 107 cells were suspended in 800 
µL ice-cold PBS/FCS and 100 µL of the antibody solution (APC-anti-CD133/1 (AC133), Miltenyi) 
were added. About 9 x 107 MCF-7/Topo cells were suspended in 9 mL ice-cold PBS/FCS, followed 
by the addition of 125 µL APC anti-mouse/human CD44 and 400 µL FITC anti-human CD24 
antibody (both BioLegend). After the incubation for 30 minutes on ice in the dark, the cells were 
washed and resuspended in ice-cold PBS/FCS to a final cell count of approximately 2 x 107 
cells/mL. Prior to the sorting procedure, the cells were filtrated through a 35 µm cell strainer (BD 
Falcon, Heidelberg, Germany) and stored on ice in the dark. The flow- and sorting rate were 
regularly checked and adjusted to reach a sort efficacy of above 90 %. Cells were sorted using a 
three-way gating strategy. Initially, dead cells and debris were gated on a two physical parameter 
dot plot (FSC/SSC) followed by the exclusion of doublets by using pulse processing (FSC-height vs. 
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FSC-area). Finally, the CD24low subpopulation was gated. Sorted cells were collected in RPMI-1640 
medium, containing penicillin-streptomycin (100 U/mL / 100 µg/mL) (Sigma, Taufkirchen, 
Germany) and subsequently used for further experiments.  
 
3.2.7 Tumorigenicity and growth kinetics of subcutaneous tumors in nude mice 
Adult, female NMRI-nu/nu mice respectively new born (24-48 hours) NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice were employed to determine the tumorigenicity and growth kinetics of 
tumor cell lines. For cell implantation, adherently growing tumor cells were washed twice with 
serum-free RPMI-1640 to remove residual FCS. Depending on the adherence of the particular cell 
line, the cells were rinsed off with medium or detached by trypsinization. Subsequently, the cells 
were washed two times with serum-free medium and the cell number was adjusted in RPMI-
1640. For sorted cell populations (see 3.2.6), the cell number was adjusted directly after the 
sorting procedure and the cells were injected immediately. For initial experiments regarding the 
growth kinetics, usually 1-3 x 106 cells in 100 µL serum-free RPMI-1640 were injected under the 
thoracic dermis of each mouse. Differences of the in vivo tumorigenicity were determined by 
injecting 103, 104, 105 respectively 106 MCF-7, MCF-7/Topo, MCF-7/Topo-CD24low (both mouse 
strains), Daoy wild type and Daoy-CD133+ cells (only NMRI-nu/nu) into each mouse. The body 
weight and tumor diameters of each mouse were monitored weekly.  
 
3.2.8 Tumor processing 
3.2.8.1 Flow cytometric characterization of tumors 
Depending on the growth rate, the tumors were excised after 2-5 months when a sufficient size 
of at least 20 mm2 was reached. Excised tumors were stored immediately in ice-cold FCS-free 
RPMI-1640. With respect to the following FACS-analysis of cell surface marker expression, tumors 
were dissected mechanically to prevent interference with proteolytic enzymes. The mechanical 
dissection was performed in ice-cold medium in 6 cm cell culture plates by cutting the tumor into 
small pieces. The tumor pieces were strained through a 40 µm mesh (BD Falcon, Heidelberg, 
Germany) which was subsequently rinsed with the medium in which the tumors were dissected 
and then washed two times with 5 mL of fresh, ice-cold RPMI-1640. For the exclusion of tissue 
and major cell agglomerates, the cell suspension was filtrated through a 40-µm cell strainer (BD 
Falcon) without mechanical pressure prior to the staining procedure (c.f. section 3.2.5.1)  
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3.2.8.2  Histology 
For the determination of the morphology, proliferative activity and formation of metastasis of 
MCF-7-tumors, tissue samples of liver, lung and the formed tumors of NSG mice were fixed in    4 
% formalin, embedded in paraffin and stained as previously described [37]. Briefly, samples were 
deparaffinized, microwave-heated for 30 min in 0.1 M citrate buffer (pH 7.3) and stained 
automatically on a Ventana Nexes autostainer (Ventana, Tuscon, USA) by using the streptavidin-
biotin-peroxidase complex method and 3.3-diaminobenzidine as chromogen. The following 
antibodies in the ultraView Universal DAB Detection Kit (Ventana, Roche) were used: anti-CK8 
monoclonal mouse anti-human (clone: 35βH11) anti-CK18 monoclonal mouse anti-human (clone: 
DC10) and anti-MIB-1/Ki-67 monoclonal mouse anti-human (clone: MIB-1) (all from 
DakoCytomation, Glostrup, Denmark). Samples were analyzed microscopically (Zeiss Axiovert 
200).  
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3.3 Investigation of human brain tumor cells 
3.3.1 Expression of CD133 and ABC-transporters 
CD133 (AC133) is a 5-transmembrane cell surface protein which was originally described as a 
marker for hematopoietic stem and progenitor cells [38, 39]. CD133-expression was detected on 
on several other cell types such as epithelial cells [40] or acute myeloid leukemia [41]. Moreover, 
CD133 is frequently used as a marker for brain tumor initiating cells (BTICs) as suggested by Singh 
et al. [7]. The glioblastoma cell lines U-87MG and LN-18, the astrocytoma cell line SW-1783 and 
the medulloblastoma cell line Daoy were analyzed for the expression of CD133. Only Daoy cells 
expressed CD133 (Fig. 3.1) and were therefore additionally analyzed for the expression of ABCB1 
and ABCG2. However, both transporters were not expressed in Daoy cells (Fig. 3.1). 
Figure 3.1: Expression of CD133 (A), ABCB1 (B) and ABCG2 (C) in Daoy cells.  
A, B: Isotype controls are depicted in inserts. C: Mitoxantrone (Mito) efflux assay with Daoy cells. 
As a control experiment, Mito efflux was inhibited by the ABCG2 modulator fumitremorgin C 
(inset). The small insets (SSC/FSC) illustrate the applied physical gates (SSC/FSC). 
 
According to the gating strategy illustrated in Fig. 3.1 A, the CD133+ subpopulation of Daoy cells 
was sorted to collect cells for the investigation of the stability of CD133 expression, the in vitro 
growth capacity and sphere formation ability (neurosphere culture) as well as the tumorigenicity 
in NMRI-nu/nu mice. However, Daoy cells proved to be inappropriate for high throughput sorting. 
The comparatively large cells caused unstable hydrodynamic focusing, resulting in low sorting 
efficiency at high flow rates. Additionally, the propensity to sediment and form agglomerates at 
high cell concentrations required an extensive dilution of the cell suspension and periodical 
resuspension of the cells. Consequently, it was impossible to sort high numbers of cells within an 
adequate period of time. 
 Investigation of human brain tumor cells 37 
 
3.3.2 Neurosphere culture and stability of CD133 expression in Daoy-CD133+ cells 
Critical properties of CICs, for example, the growth capacity and sphere formation ability, can be 
monitored under special in vitro culture conditions. For this purpose, a combination of a serum-
free culture medium, only supplemented with specific growth factors, and the incubation in non-
adherent cell culture conditions (ultra-low attachment plates) was used (sphere culture). 
Theoretically, these conditions allow for the maintenance of undifferentiated stem cells and the 
proliferation of multipotent, self-renewing stem cells [7]. By serial passaging under these 
conditions, it was possible to estimate the growth capacity of the respective cells.  
Figure 3.2: Expression of CD133 in Daoy wild type (A), freshly sorted Daoy-CD133+ (B) and Daoy-
CD133+ cells after 14 days in neurosphere culture (C). Isotype controls are illustrated in the insets. 
Small inserts depict the applied gating strategy (SSC/FSC). 
 
The sphere formation ability in limiting dilution assays was compared for Daoy wild type and 
Daoy-CD133+ cells. Within 24 hours after seeding of more than 300 cells per well, Daoy-CD133+ 
cells formed definite spheres, whereas Daoy wild type cells formed loosely adherent aggregates. 
However, both cell types could be cultured for several passages over a period of 3 weeks under 
these conditions without significant changes of growth. The CD133 expression by the sorted 
Daoy-CD133+ cell population, maintained in neurosphere culture for a period of 2 weeks, was re-
analyzed by flow cytometry. Interestingly, the phenotype reverted with respect to CD133 
expression, resembling the Daoy wild type cells (Fig. 3.2). In contrast to the comparable growth 
capacity of Daoy wild type and Daoy-CD133+ cells, the sphere formation ability in limiting dilution 
assays was significantly different. Daoy wild type cells formed irregularly shaped aggregates only 
at cell counts above 100 cells per well, whereas Daoy-CD133+ cells formed spheres with diameters 
of around 100 µm within 9 days (Fig. 3.3), even when only 1 cell/well was seeded (Table 3.1). 
Interestingly, the maximum number of spheres was comparable, regardless of the number of 
Daoy-CD133+ cells seeded: 300 or 1000 cells/well resulted in 3-5 spheres of different size. 
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3.3.3 Tumorigenicity of Daoy and Daoy-CD133+ cells 
Different numbers of Daoy and sorted Daoy-CD133+ cells were subcutaneously injected into nude 
mice (NMRI-nu/nu). The injection of 106 Daoy wild type cells led to the formation of tumors in 7 
out of 12 mice within 3 months. When 1.5 x 105 Daoy cells were injected, 1 out of 3 mice 
developed a tumor. By contrast, tumor formation was not observed after injection of 1.5 x 105 or 
1.5 x 104 sorted Daoy-CD133+ cells. Due to inefficient cell sorting, higher amounts of Daoy-CD133+ 
cells were not available to perform additional experiments. However, there is no hint to increased 
tumorigenicity of Daoy-CD133+ compared to wild type cells in this mouse model. 
 
3.3.4 Flow cytometric characterization of Daoy tumors 
The tumors formed after the injection of Daoy cells did not allow the preparation of single cell 
suspensions. Accordingly, flow cytometric analysis revealed mainly no live cells, precluding the 
determination of the expression of CD133, ABCB1 and ABCG2. With regard to possible impacts 
on flow cytometric measurements, enzymatic methods for tumor disaggregation were not 
applied. 
 
 
Figure 3.3: Limiting dilution assay with Daoy-CD133+ 
(A-F) and Daoy cells (G-I). Formed spheres, 9 days 
after seeding of 1 (A), 3 (B), 10 (C), 30 (D), 100 (G), 
300 (E, H) and 103 (F, I) cells/well. 
Table 3.1: Number of spheres (± 
SEM) formed per well after 
seeding of different numbers of 
CD133+ cells (n=2). 
Cells/well Spheres/well 
100            2.2 ± 0.0 
30 2.1 ± 0.3 
10 1.4 ± 0.1 
3 0.7 ± 0.2 
1 0.4 ± 0.01 
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3.3.5 Discussion  
The flow cytometric examination of CD133 expression in human brain tumor cells (Daoy, LN-18, 
U-87MG, SW-1783) revealed a subpopulation of CD133+ cells only in Daoy medulloblastoma cells. 
A side population expressing ABCG2 or ABCB1 was not observed in Daoy cells. In contrast to the 
extent of sphere formation of sorted Daoy-CD133+ cells, compatible with the concept of CIC-like 
properties, the ability to form tumors in nude mice was not enhanced. On the contrary, slow 
restoration of a CD133- subpopulation (50 % after 2 weeks) suggests a preferential growth of 
CD133- cells. This slow process may result from asymmetric divisions, a stem cell property [42], 
or the preferential growth of a small number of residual CD133- cells. Plasticity of CICs, as recently 
reported for breast cancer cells [43], should result in a faster re-adjustment of initial proportions 
of CD133- and CD133+ cells. Additional investigations including markers of BTICs, such as nestin 
[44], could help to decide whether Daoy-CD133+ cells can be considered CICs. However, Daoy cells 
turned out to be inappropriate for high throughput cell sorting, compromising further 
experiments regarding cancer initiating cells, although a CD133+ subpopulation indicated at least 
increased clonogenicity in vitro. 
Previously, CD133- glioma cells were also described as highly tumorigenic [45]. According to a 
recent publication the validity of CD133 as a universal marker of cancer initiating cells is doubtful 
[46].  
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3.4 Investigation of human breast cancer cells 
3.4.1 Expression of CD24, CD44, ABCB1 and ABCG2  
Since Al-Hajj et al. [11] described a tumorigenic CD24-/low/CD44+ subpopulation in breast cancer 
cells, this marker combination is most commonly used for the identification of breast cancer 
initiating cells (BCICs). All breast cancer cell lines examined in this study were CD44+, whereas the 
expression of CD24 varied in a wide range (Fig. 3.4). The expression of ABCB1 and ABCG2 was 
additionally determined. Apart from a weak ABCG2-expression in JIMT-1 cells and the induced 
ABCG2 expression in MCF-7/Topo and MCF-7/Topo/wo cells, none of the cell lines comprised cells 
expressing ABCB1 or ABCG2. The comparison of results obtained by mitoxantrone efflux and the 
antibody-based determination of ABCG2 transporters in MCF-7/Topo cells revealed a better 
distinction between ABCG2- and ABCG2+ cells using the specific antibody (Fig. 3.5).  
Figure 3.4: Expression of CD24/CD44 (left) and ABCG2 (right) in breast cancer cell lines. 
Left panel: Expression of CD24 (y-axes) and CD44 (x-axes) in ZR-75-1, JIMT-1, HCC1937 and MDA-
MB-231 cells. The respective isotype controls are depicted in red. The small insets illustrate the 
applied physical gating strategy (SSC/FSC). Right panel: Mitoxantrone efflux as indicator of ABCG2 
activity in ZR-75-1 and JIMT-1 cells. Mitoxantrone efflux was inhibited by fumitremorgin C (FTC) 
(insets). The small insets illustrate the applied physical gates (SSC/FSC).  
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Figure 3.5: Flow cytometric determination of ABCG2 expression in MCF-7/Topo cells with anti-
ABCG2-pacific blue antibody (A) and the mitoxantrone-efflux (Mito) assay (B). Isotype control 
respectively Mito efflux inhibited by fumitremorgin C (FTC) are illustrated as black line. Mean 
fluorescence intensities (MFI) are shown in the inserted tables. 
 
3.4.2 Tumorigenicity of MDA-MB-231 cells 
As stated in section 3.4.1, the triple negative breast adenocarcinoma cell line MDA-MB-231 
exhibited the CD24-/low/CD44+ expression level which described for breast cancer initiating cells. 
The tumorigenicity of MDA-MB-231 cells was investigated in NMRI-nu/nu mice. The injection of 
2 x 106 cells resulted in tumor formation in 4 out of 20 mice within 4 months.  
 
3.4.3 Discussion 
The CD24-/CD44+ expression pattern is the most frequently used marker combination to identify 
breast cancer initiating cells. However, the abundance of CD44 on carcinoma cells of diverse 
entities [18], but particularly on breast cancer cells appears surprising for a cancer initiating cell 
marker. The investigation of CD24/CD44 expression in diverse breast cancer cell lines revealed 
that the CD24-/low phenotype is the unique characteristic of the CD24-/CD44+ cell population since 
the vast majority of all cell lines was CD24+/CD44+. Only HCC1806 and HCC1937 exhibited a weak 
CD24 expression, comprising a small CD24low subpopulation. By contrast, more than 80 % of MDA-
MB-231 cells were CD24-/CD44+. Besides, MDA-MB-231 cells revealed the highest CD44 
expression of all examined cell lines. None of the examined cell lines revealed ABCB1 expression, 
and only JIMT-1 (and the ABCG2 induced MCF-7/Topo) cells comprised a side population 
expressing ABCG2. Contrary to the expected high tumorigenicity of the CD24-/CD44high MDA-MB-
231 cells, the take rates after the injection of 2x106 cells in NMRI-nu/nu mice were poor (4 tumors 
in 20 mice), suggesting that this phenotype is not necessarily linked to enhanced tumorigenicity. 
Notably, a lack of correlation between breast cancer stem cell markers (CD24low/CD44+/EpCAM+) 
and tumorigenicity was recently reported [48].   
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3.5 Effects of topotecan treatment on MCF-7 cells 
Note: This results have been submitted for publication under the title “Topotecan-induced ABCG2 
expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of 
tumorigenicity”, prior to the submission of this thesis. 
 
3.5.1 Expression profile of ABCG2 and ABCB1 in different MCF-7 variants 
The topoisomerase inhibitor topotecan is widely used in cancer therapy, especially in the 
treatment of ovarial carcinoma and small cell bronchial carcinoma. It is a known substrate of the 
breast cancer resistance protein ABCG2 and long-term treatment of cancer cells in vitro leads to 
the induction of ABCG2. The function of the ABCG2 transporter was determined in the 
mitoxantrone efflux assay, and the expression was confirmed with a pacific blue coupled 
monoclonal antibody against an extracellular part of the protein (data not shown). While MCF-7 
cells did not express the ABCG2 transporter, topotecan-treatment induced a high and 
homogenous expression of ABCG2 in MCF-7/Topo cells (Fig. 3.6). MCF-7/Topo cells cultivated in 
topotecan-free medium (MCF-7/Topo/wo cells) maintained the expression level of ABCG2 over a 
period of approximately 6 weeks. Later on, a small proportion of the cells (approx. 12 % after 10 
weeks cultivation in the absence of topotecan) lost the ability of mitoxantrone efflux, whereas 
high expression of ABCG2 persisted in the majority of the cells. Comparing the ratio of the mean 
fluorescence intensities (RMFI) between Mito+ (ABCG2 mediated mitoxantrone-efflux inhibited by 
FTC) and Mito- (ABCG2 mediated mitoxantrone-efflux) cells revealed no significant difference for 
Figure 3.6: Expression of ABCG2 in MCF-7, MCF-7/Topo and MCF-7/Topo/wo cells. 
Flow cytometric measurement of Mito efflux as indicator for ABCG2 activity in MCF-7 (A), MCF-
7/Topo (B) and MCF-7/Topo/wo (C) (10 weeks in topotecan-free medium) cells. Mito efflux was 
inhibited by fumitremorgin C (FTC) (black line). A: MCF-7 cells do not express ABCG2. B, C: red 
line: uninhibited ABCG2-mediated efflux of Mito. black line: inhibition of Mito efflux by FTC. The 
inserts illustrate the applied physical gates (SSC/FSC). Mean fluorescence intensities are given in 
the inserted tables.  
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MCF-7/Topo (RMFI = 5.7 ± 1.3) and MCF-7/Topo/wo cells (RMFI = 5.4 ± 0.3) after cultivation over 10 
weeks in the absence of topotecan (Fig. 3.6). ABCB1 (P-gp) expression was determined by the use 
of a monoclonal antibody. Topotecan treatment had no effect on the expression of ABCB1, since 
both cell variants, MCF-7 and MCF-7/Topo, were ABCB1 negative (data not shown). 
 
3.5.2 Expression of CD24, CD44, EpCAM and HER2 in MCF-7 variants 
The HER2 receptor and the cell surface proteins CD24, CD44, and EpCAM are important markers 
for breast cancer cell phenotyping. MCF-7 cells express all four marker proteins (CD24+, CD44+, 
EpCAM+, HER2+). However, long-term treatment of MCF-7 cells with topotecan caused a 
significantly altered CD24, EpCAM and HER2 expression profile with the most pronounced effect 
on CD24: The previously homogenous expression in MCF-7 cells became heterogenous, and the 
Figure 3.7: Expression of CD24, CD44, EpCAM and HER2 in different MCF-7 variants. 
A: Expression of CD24 and CD44 in MCF-7, MCF-7/Topo and MCF-7/Topo/wo (6 weeks in 
topotecan-free medium) cells. Isotype controls in the dot plots are depicted in red. The applied 
gating strategy is illustrated in the small inserted two parameter (SSC/FSC) dot blots.  
B: Expression of EpCAM (a) and HER2 (b) in MCF-7 (filled) and MCF-7/Topo (empty) cells. Mean 
fluorescence intensities (MFI) are shown in the inserted tables. Isotype controls are illustrated in 
the small inserts. 
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overall expression level decreased distinctly, resulting in 10 to 15 % CD24low cells. (Fig. 3.7 A) While 
the expression of CD44 remained virtually unaffected by topotecan treatment, EpCAM was 
downregulated by 45 % and HER2 was up-regulated by 60 % (Fig. 3.7 B). Unlike the expression of 
ABCG2, which was quite stable in culture in the absence of topotecan, the expression level of 
CD24 in MCF-7/Topo/wo cells recovered within 6 weeks to the initially homogenous expression 
level as observed in MCF-7 cells (Fig. 3.7 A). The CD24low subpopulation of MCF-7/Topo cells was 
sorted and tumorigenicity as well as mammosphere formation capacity in vitro was assessed. A 
high degree of purity in CD24low sorted cells (referred to as MCF-7/Topo-CD24low) was confirmed 
(>98 %, data not shown). 
 
3.5.3 Chemosensitivity of MCF-7 and MCF-7/Topo cells 
Doxo, MTX, and 5-FU are often used in different combinations with other drugs for chemotherapy 
of breast cancer [47]. The cytotoxic effect of these cytostatic drugs was determined as an 
indicator of the induction of ABCG2 transporter expression. The IC50 values of Doxo and MTX on 
MCF-7 cells were in a low nanomolar range (Table 3.2). On the contrary, MCF-7/Topo cells 
revealed a 1.5 fold increase in the IC50 value of MTX (p < 0.05) and 4.0 fold increased IC50 value of 
Doxo (p < 0.001). However, MTX treatment did not induce a cytocidal drug effect, neither in MCF-
7 nor in MCF-7/Topo cells, but resulted in a decrease of the cell number by 70 % compared to the 
untreated control. 5-FU exhibited cytotoxic effects in considerably higher concentrations (Table 
3.2) than Doxo and MTX, but revealed no significant difference regarding the IC50 value in both 
cell lines.  
 
3.5.4 Mammosphere culture and limiting dilution assays 
In adherent cell culture MCF-7 and MCF-7/Topo cells exhibited no significant difference in the 
growth characteristics: Both cell variants revealed epithelial, polygonal morphology and showed 
comparable doubling times (MCF-7: 22.8 ± 1.7 hours; MCF-7/Topo: 23.4 ± 0.9 hours; n = 3). 
Mammosphere formation under non adherent growth conditions was assessed to examine the 
tumor initiating capacity of MCF-7, MCF-7/Topo, and MCF-7/Top-CD24low cells. Therefore, the 
Table 3.2: IC50 values (± SEM, n = 3) in nM of Doxo, MTX, and 5-FU determined in MCF-7 and MCF-
7/Topo cells after 72 hours of incubation. 
Compd. Cell variant 
MCF-7 MCF-7/Topo 
Doxo 19.7 ± 4.7 77.4 ± 6.9 
MTX 19.2 ± 0.3 32.1 ± 3.1 
5-FU 2440 ± 235 2325 ± 435 
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growth capacity (sphere size) and cell propagation after serial passaging and the ability to form 
spheres out of small cell numbers (limiting dilution) were determined. All cell variants were 
principally capable of forming spheres, but MCF-7 cells produced spheres with a larger diameter 
(200 – 300 µm) compared to MCF-7/Topo and MCF-7/Topo-CD24low cells (diameter 100 µm, 
respectively), which formed an increased number of spheres instead. However, MCF-7 and MCF-
7/Topo cells showed comparable long-term growth characteristics; serial passaging revealed no 
decline in growth for at least three weeks when cells were passaged 2-3 times a week. In contrast, 
the CD24low cell population lost the capacity to proliferate after a few passages within 2-3 weeks 
which was due to the formation of vacuole-like structures and cell disintegration / lysis (Fig. 3.8 
left panel). For limiting dilution assays cell numbers between 1 and 103 (adjusted by serial 
dilution) MCF-7, MCF-7/Topo and sorted MCF-7/Topo-CD24low cells were seeded per well and 
incubated for 12 days.  
 
Figure 3.8: Mammosphere culture of MCF-7 and MCF-7/Topo-CD24low cells.  
Left panel: Formed spheres at day 6 (A, C) and day 12 (B, D) after seeding of MCF-7 (A, B) and 
MCF-7/Topo-CD24low (C, D) cells, respectively. MCF-7 cells pursue to grow, while MCF-7/Topo-
CD24low underwent cell lysis and sphere disaggregation (D). 
Right panel: Numbers of spheres formed per well after limiting dilution of MCF-7 and MCF-
7/Topo-CD24low cells. (Mean ± SEM, n = 3)  
 
The mammosphere forming ability was not significantly different for all cell variants. All cell types 
formed spheres when 30-1000 cells were seeded, while MCF-7 formed again larger spheres (Fig. 
3.8 A and B) than MCF-7/Topo-CD24low cells (Fig. 3.8 C and D). However, number of formed 
spheres after seeding 30 or 100 cells per well was not significantly different for all examined cell 
variants (Fig. 3.8 E). In none of the cell types sphere formation was observable when 10 cells or 
less were seeded.  
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3.5.5 In vivo investigations of MCF-7 variants 
Beyond the assessment of mammosphere formation in vitro the tumorigenicity of MCF-7, 
MCF-7/Topo and MCF-7/TopoCD24low cells was determined in newborn NSG respectively adult 
NMRI-nu/nu mice. For this purpose, different cell numbers of the respective cell variant were 
subcutaneously injected and the tumor growth as well as the body weight was monitored over a 
period of 3-5 months. The tumorigenicity was considerably higher in newborn NSG-mice than in 
NMRI-nu/nu mice (Table 3.3). The injection of only 1 x 105 MCF-7 cells led to the formation of 
tumors (3 of 3 mice; Fig. 3.9 A), while at least 1 x 106 cells were required to induce tumor growth 
in NMRI-nu/nu mice (2 of 6 mice). The in vivo tumorigenicity of MCF-7 and MCF-7/Topo cells was 
compared after injecting 1 x 106 cells into NMRI-nu/nu mice (n = 6). MCF-7 cells formed tumors 
in 2 of 6 mice, while the injection of MCF-7/Topo cells did not result in tumor growth. Additionally, 
the tumor-initiating efficacy of MCF-7 and sorted MCF-7/Topo-CD24low cells in NMRI-nu/nu mice 
was compared as a function of 1 x 103 and 1 x 106 injected cells (n = 3 for each cell number). Unlike 
MCF-7 cells, which formed tumors after injection of 1 x 106 cells in 33 % of used mice, the injection 
of MCF-7/Topo and MCF-7/Topo-CD24low cells did not result in tumor growth. The impaired 
tumorigenicity of MCF-7/Topo-CD24low cells could be confirmed in the NSG-mouse model (Fig. 
3.9 B). MCF-7 cells showed tumor growth even after the injection of only 105 cells while MCF-
7/Topo-CD24low cells only formed slowly growing tumors after the injection of 106 cells.  
 
Tumors were excised after 3-5 months and analyzed by histology and flow cytometry. In 
histological specimens CK8, CK18, and Ki67 stainings [48, 49] were performed to verify the 
presence (CK8, CK18) and proliferation capacity (Ki67) of injected, human tumor cells (Fig. 3.9 
lower panel). All examined tumors arose at the site of injection and developed epithelial 
morphology. The histological examination of liver and lung revealed no evidence for metastases. 
Flow cytometric measurements of MCF-7 tumors revealed a CD24low/CD44high subpopulation (2.8 
% ± 1.0 (SEM, n = 3)) while 46.9 % ± 2.9 (SEM, n = 3) of solid cancer cells showed a CD24-, CD44-, 
Table 3.3: Tumorigenicity of MCF-7, MCF-7/Topo and MCF-7/Topo-CD24low cells in NMRI-nu/nu 
and NSG mice. Take rate, expressed as number of tumors per number of injected mice.  
Cell 
number 
NMRI-nu/nu   NSG 
MCF-7 
MCF-
7/Topo 
MCF-7/Topo-
CD24low  
 
MCF-7 
MCF-7/Topo-
CD24low 
106 3/9 0/9 0/3    3/3 2/2 
105 0/3 0/3 0/3   3/3 0/2 
104 0/3 0/3 0/3   0/3 0/2 
103 0/3 0/3 0/3    n. d. n. d. 
n. d.: not determined 
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EpCAM-, and HER2- phenotype (Fig. 3.9 C). In tumors which were formed after the injection of 
MCF-7/Topo-CD24low cells, the majority of cells remained a CD24low, CD44+, EpCAM+ and HER2+ 
expression. Only small subsets of approximately 5 % of CD24+/CD44+ and 3 % CD24low/CD44high 
cells were observed. In addition, the rate of EpCAM/HER2 negative cells was lower (27 %) than in 
MCF-7 tumors (47 %). 
 
Figure 3.9: Flow cytometric and immunohistological analyses of excised tumors (NSG-mice). 
A: Size and shape of MCF-7 tumors formed in different mice. B: Final size of formed tumors [mm3] 
after the injection of different cell numbers of MCF-7 and MCF-7/Topo-CD24low cells.      C: Flow 
cytometric analysis of tumor cell suspensions, prepared from MCF-7 or MCF-7/Topo-CD24low 
tumor tissue. Respective flow cytometric analyses of MCF-7 respectively MCF-7/Topo cells are 
shown as inserts. Lower panel: Expression of CK8, CK18 and Ki67 in MCF-7 tumor cells visualized 
by immunohistochemistry.  
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3.5.6 Discussion 
ABCG2 transporter expression in tumor cells is induced upon treatment with a variety of 
cytostatic drugs and enables the efflux of different chemotherapeutics (multidrug resistance). 
ABCG2 activity can be experimentally identified in so-called “side populations”. Since those “side 
populations” have been considered to comprise CICs, we examined the effect of cytotoxic 
treatment on the expression of CD24, CD44, EpCAM, and HER2, which all are supposed to 
enhance tumorigenicity, tumor progression, and metastasis. For example, a CD24- phenotype has 
been linked to treatment-resistant breast cancer cells [50, 51], whereas another group reported 
the enrichment of a highly tumorigenic CD24- subpopulation as a result of anti-Her2 treatment 
with Trastuzumab in the presence of natural killer cells [52]. Hence, we assessed the capacity of 
mammosphere formation in MCF-7 cells in vitro and tumor outgrowth in immunodeficient mice 
as a function of treatment with Topo.  
We report that long-term exposure of MCF-7 breast cancer cells to Topo led to a homogenously 
high expression level of ABCG2 (= MCF-7/Topo), which remained stable for several weeks after 
removal of Topo. As expected, MCF/Topo cells exhibited an increased chemoresistance against 
cytostatic drugs like Doxo and MTX (i.e. ABCG2-substrates) [1]. However, the induction of ABCG2 
in MCF-7/Topo cells under chemotherapeutic pressure did not result in an increased capacity to 
form mammospheres. By contrast, MCF-7/Topo cells revealed a considerably decreased 
tumorigenicity compared to MCF-7 cells. These findings suggest that the induction of ABCG2 upon 
Topo treatment does not induce cells with enhanced cancer-initiating properties. It has been 
reported that ABCG2- cells tended to form tumors more efficiently than ABCG2+ cells [53]. ABCG2 
expression was indicative of fast-cycling tumor progenitors, whereas the ABCG2- population 
expressed genes which are generally associated with “stemness”. The decreased tumorigenicity 
of the ABCG2+ cell variant MCF-7/Topo as observed in this study may be attributed to the 
concurrent Topo-treatment related downregulation of CD24 and EpCAM, which has not been 
analyzed in the context of ABCG2 expression so far. However, it remains to be examined whether 
Topo treatment causes both, increased ABCG2 and decreased CD24/EpCAM expression, or 
whether the reduced CD24/EpCAM expression is a consequence of ABCG2 upregulation. Apart 
from that, the increased CD24low/EpCAMlow subpopulation could either originate from the 
selection of a pre-existing subpopulation or by a real downregulation of those markers. 
Nevertheless, the association of CD24 with tumor clonogenicity becomes obvious from the 
considerably reduced mammosphere formation in vitro and tumor outgrowth in vivo of sorted 
MCF-7/Topo-CD24low cells. Notably, a positive correlation between high CD24 expression and 
enhanced cell proliferation in vitro and in vivo was reported previously [16]. For example, CD24+ 
cells from pleural effusions of different carcinomas revealed increased tumorigenicity in 
immunodeficient mice [54]. Further evidence for the impact of CD24 was previously provided by 
the comparison of CD24low and CD24high subpopulations of MCF-7 cells [55]. The CD24high 
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subpopulation proliferated faster and exhibited increased adhesion and invasiveness in vitro. 
However, the expression of ABCG2 and the sensitivity against doxorubicin did not differ between 
both cell types. Moreover, CD24 has been suggested to be involved in the metastatic process. It 
has been described to be involved in tumor cell dissemination/seeding by mediating an 
interaction of tumor cells with platelets and endothelial cells [56].  
The concurrent downregulation of EpCAM in MCF-7 cells upon treatment with Topo, as observed 
in this study, is likely to enhance the impact of reduced CD24 expression on clonogenicity and 
tumorigenicity. While high EpCAM expression levels obviously favor cell aggregation [57] lower 
expression of EpCAM impairs mammosphere formation of MCF-7/Topo cells. Alike CD24, the 
EpCAM molecule is apparently involved in cell migration and invasive growth [58, 59]. However, 
the regulation of EpCAM during metastasis is postulated to be more complex: EpCAM positive 
but also negative circulating and disseminated tumor cells have been reported, although cell 
migration would rather implicate a low EpCAM expression. Conversely, the subsequent tissue 
invasion as well as the formation of micrometastases would require distinct EpCAM expression 
[60]. 
In the past, a number of distinctive biomarker patterns have been associated to breast cancer 
stem cells. Nevertheless, a definite or unique stem cell phenotype could not be established, 
whereas even a pronounced plasticity of cell populations with distinct marker expression patterns 
(CD24, CD44, EpCAM) was recently reported [43]. Moreover, even a missing correlation of a 
typical profile of breast cancer stem cell markers (i.e., CD24low, CD44high, ALDHhigh, EpCAMlow) and 
enhanced tumorigenicity has been reported [61]. The present study substantiates existing 
evidence for the importance of CD24 and EpCAM in tumor formation and outgrowth. Beyond 
that, the data indicate that induced ABCG2 expression is not necessarily linked to a more 
aggressive phenotype. 
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3.6 Conclusion 
Distinct cancer initiating cell marker expression was found in Daoy (brain tumor), MDA-MB-231, 
HCC1806 and HCC1937 (triple negative breast cancer) cells. The sorted Daoy-CD133+ 
subpopulation revealed also significantly enhanced clonogenicity in vitro. However, Daoy cells 
showed inappropriate characteristics for cell sorting, impeding investigations with high numbers 
of sorted cells. Furthermore, overall poor take rates in NMRI-nu/nu mice hampered the in vivo 
investigations of brain (Daoy) and breast cancer (MCF-7) cell lines. Apart from that, evidence for 
lacking correlations between established markers of cancer initiating cells and tumorigenicity 
were provided for MDA-MB-231 cells, which underlines the importance of the combination of 
several markers with in vivo experiments.  
The treatment of MCF-7 breast cancer cells with topotecan induces ABCG2-expression and thus 
leads to increased cellular resistance against cytostatic drugs which are substrates of the 
transporter molecule. Concurrently, topotecan treatment resulted in a persisting but reversible 
reduction of CD24 and EpCAM expression. This phenotype modification was not associated with 
an enhanced, but rather with a reduced clonogenicity and tumorigenicity. Nevertheless, further 
investigations are necessary to determine whether ABCG2 induction and CD24/EpCAM 
downregulation, respectively the selection of a CD224low/EpCAMlow subpopulation are correlated 
or independent processes. 
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4 Chapter IV 
Stabilities of neutral and basic esters of 
bendamustine in plasma compared to the 
parent compound: Kinetic investigations by 
HPLC 
 
 
 
 
 
 
Note: As stated in the list of publications, this chapter has already been published prior to the 
submission of this thesis [1]. For detailed information on the contribution of other authors see also 
“Acknowledgements”.  
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4.1 Introduction 
Bendamustine (1, Fig. 4.1), first synthesized in 1963 [2, 3], was brought on the market in East 
Germany under the name “Cytostasan” for the treatment of chronic lymphatic leukemia (CLL), 
non-Hodgkin lymphoma (NHL), Hodgkin disease, multiple myeloma (MM) and breast cancer [4-
7]. After passing out of mind, it was rediscovered in the 1990s and marketed in North America. 
Today, bendamustine is approved for CLL [8, 9], indolent NHL [10] and MM [11, 12] in Germany 
and for CLL and indolent NHL in the US.  
 
Figure 4.1: Structures of bendamustine (1) and the bendamustine esters 2-9.  
 
As a nitrogen mustard derivative, 1 is instable in aqueous solutions, in particular at neutral or 
basic pH values [13], resulting in the inactive bis(2-hydroxyethylamino)-substituted 
benzimidazole derivative upon twofold hydrolysis. Several HPLC methods for the determination 
of bendamustine and related compounds, degradation products and metabolites are reported in 
the literature, using UV [14-16], fluorescence [17] and mass spectrometric [18, 19] detection.  
Bendamustine is provided as a lyophilized powder for preparation of solutions prior to 
intravenous administration [20]. Recent patent applications aimed at improved oral 
bioavailability of bendamustine by optimized formulations [21-23]. Simple alkyl esters (e. g. 
methyl and ethyl ester) of 1 are mainly known as synthetic intermediates [24, 25]. Dimeric and 
dendrimeric bendamustine derivatives were investigated with respect to cytotoxicity [26, 27], and 
C1 – C24 alkyl esters were reported as prodrugs to prepare formulations for intravenous injection 
[28]. In a different approach, exploring the potential of derivatives of 1, very recently, esters of 
bendamustine (compounds 2-7 (Fig. 4.1) cf. ref. [29]) proved to possess considerably increased 
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antiproliferative activity compared to the parent compound against a panel of different cancer 
cell types [29]. The increase in potency strongly depended on the chemical properties of 
substituent R (cf. Fig 4.1), with highest activities residing in esters bearing a basic moiety such as 
pyrrolidinoethyl, piperidinoethyl, or morpholinoethyl (mofetil) ester, though ordinary alkyl 
(methyl, ethyl) esters were also more cytotoxic than the parent compound. In case of these 
derivatives of 1, the spectrum of possible degradation products becomes more complex in a 
biological environment, where, in addition to nucleophiles attacking the nitrogen mustard 
moiety, hydrolytic enzymes may contribute to degradation. Here we report on the analytical 
investigation of the stability of esters of 1, depending on the chemical nature of the substituent 
R in different media, taking into consideration the possible routes of chemical and enzymatic 
cleavage suggested in Figure 4.2. For this purpose, we established a RP-HPLC method with 
fluorescence detection for the determination of bendamustine, bendamustine esters and related 
hydrolysis products. 
 
Figure 4.2: Possible routes of degradation of bendamustine (1) and esters 2-9 due to hydrolysis 
of the nitrogen mustard moiety and (enzymatic) ester cleavage, respectively. 
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4.2 Materials and Methods 
4.2.1 Chemicals and reagents 
Bendamustine-HCl as well as the esters 2-7 [29] were provided by Arevipharma GmbH (Radebeul, 
Germany). Compounds 8 (1) and 9 (1) (Fig. 4.1) were synthesized in our laboratory (for synthesis 
protocols and analytical data cf. master thesis of F. Antoni [30]). Physostigmine, umbelliferone, 
porcine liver esterase and o-nitrophenyl butyrate were from Sigma-Aldrich (Taufkirchen, 
Germany). HPLC-grade acetonitrile was obtained from Fisher Scientific (Schwerte, Germany). 
Demineralized water was purified with a Milli-Q system (Merck KGAa, Darmstadt, Germany). All 
other reagents, if not otherwise stated, were of analytical grade and from Sigma-Aldrich 
(Taufkirchen, Germany).  
 
4.2.2 Analytical procedures 
4.2.2.1 Instumentation 
HPLC analyses were performed with a system from Thermo Separation Products (Dreieich, 
Germany), consisting of a SN 4000 Controller, a P4000 pump, an AS3000 autosampler, a Spectra 
Focus 2000 UV‐Vis detector a FL3000 fluorescence detector and a SCM 400 solvent degasser. A 
Synergi Hydro RP column (4 µm; 80A; 250 x 4.0 mm), equipped with a guard cartridge (AQ C18, 
Phenomenex, Aschaffenburg, Germany) was used for separation of the analytes.   
 
4.2.2.2 HPLC conditions  
The mobile phase consisted of NaH2PO4 (10 mM, pH 3.0) (A), filtrated through a 0.22 µm Steritop-
GP filter (Merck, Darmstadt, Germany) and acetonitrile (B). Both eluents were degassed with 
helium prior to use. For all analyses, the injection volume was 50 µL, and a linear gradient from 5 
– 50 % B within 15 min at a flow rate of 0.75 mL/min and a column temperature of 30 °C was 
used. Fluorescence detection was performed at an excitation wavelength of 330 nm and emission 
at 420 nm. Void volume was determined with uracil. 
 
4.2.2.3 Standards and calibration 
Solutions of 1-9 and of the internal standard umbelliferone were prepared in dimethyl sulfoxide 
(DMSO). The identities of the reference compounds (“standards”), umbelliferone, bendamustine 
(1) and 4-{5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-yl}butanoic acid (1b) 
                                                     
1 Synthesized and examined by F. Antoni [30].  
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were confirmed by LC-MS and 1H NMR spectroscopy, respectively (data not shown). For 
calibration, solutions of 1-9 (at least 8 concentrations between 5 nM and 30 µM) were prepared 
by serial dilution of the stock solutions with an aqueous solution of NaH2PO4 (10 mM) adjusted to 
pH 2.0 with phosphoric acid. In case of the internal standard (umbelliferone), nine different 
concentrations (5 nM - 25 µM), obtained by dilution with phosphate solution pH 2.0, were used 
for calibration.  
 
4.2.3 Determination of the stability of bendamustine and bendamustine esters  
4.2.3.1 Stability in phosphate buffer 
Stock solutions (3 mM) of 1-7 were diluted with phosphate buffer (10 mM Na2HPO4, pH was 
adjusted to 7.4 with phosphoric acid) to a final concentration of 30 µM. After different periods of 
incubation (0, 7.5, 15 and 30 min) at 37 °C, hydrolysis of the nitrogen mustard moiety was stopped 
by adding 20 µL of the sample to 180 µL ice cold acidic phosphate solution (10 mM, pH 2.0). After 
filtration (Phenex-RC 4-mm Syringe Filters 0.2 µm; Phenomenex), 50 µL of this solution were 
injected into the HPLC system. 
Half-lives were calculated from plots of peak areas versus time, using the “one phase exponential 
decomposition” option of GraphPad Prism 5 (GraphPad Software, La Jolla, USA). 
With respect to the preferred deproteination procedure and the sample preparation and storage, 
the stability of the analytes was assessed in PBS containing 0.5 M perchloric acid at 4 °C over a 
period of 8 h. 
 
4.2.3.2 Stability in human and murine plasma 
Human CPD (citrate, phosphate, dextrose)-plasma was a gift from the Bavarian Red Cross. Murine 
blood was collected from nude mice (NMRI-nu/nu) by cardiac punction using heparin-coated 
syringes. Blood samples were immediately stored on ice until the cellular components were 
removed by centrifugation at 4 °C and 5000 g for 10 min. The plasma samples were stored at -80 
°C.  
Solutions of 1-9 (20 µL, 1 mM) were mixed with 180 µL of a 200 µM solution of the internal 
standard (umbelliferone) in phosphate buffered saline (PBS). Afterwards, this mixture was added 
to human or murine plasma, giving a concentration of 10 µM of 1-9. 
After incubation at 37 °C for different periods, depending on the individual compound, 
deproteination of the samples was performed by adding the same volume of ice-cold perchloric 
acid (1 M) and vortexing. After storage for 20 min at 4 °C and subsequent centrifugation of the 
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samples (3 min, 4 °C, 16,000 g; Eppendorf Centrifuge 5415 R, Hamburg, Germany), the 
supernatants were filtrated (Phenex-RC 4-mm Syringe Filters 0.2 µm; Phenomenex) and stored 
on ice until HPLC analysis. To inhibit unspecific esterases (butyrylcholinesterase) in human 
plasma, samples were incubated with physostigmine (100 µM) at 37 °C for 30 min prior to the 
addition of the esters 4 and 5. 
 
4.2.3.3 Stability depending on protein concentration 
The influence of the protein concentration on the stability of different bendamustine derivatives 
was determined by analogy with the stability in plasma, except for the replacement of plasma by 
a solution of porcine liver esterase (5.48 U/mL) in PBS, containing different concentrations of 
bovine serum albumin (BSA) ranging from 20 mg/mL to 70 mg/mL. The most pronounced effect 
was observed at concentrations from 30 mg/mL to 50 mg/mL. 
 
4.2.3.4 Determination of the activity of unspecific esterases 
Esterase activity was determined photometrically using o-nitrophenyl butyrate as substrate [31, 
32]. o-Nitrophenyl butyrate (40 µL of a 100 mM stock solution in DMSO) was mixed with 1 mL of 
phosphate buffer (0.1 M, pH 7.4). When the solution had reached 37 °C, 10 µL of murine or human 
plasma were added, and the increasing absorbance was recorded at 414 nm for 4 min. The volume 
activity VA was determined from the initial rate according to the following equation: 
VA=(ΔA / t) . V / (ε . d . v)  
(Volume activity VA (µmol . min-1 . mL-1), ΔA = increase in absorbance at 414 nm, ε = 3190 L . mol-1 . 
cm-1 [33], d = path length (cm), V = total volume (mL), v = volume of enzyme/plasma containing 
solution (mL)) 
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4.3 Results 
4.3.1 Validation of the HPLC-method 
The analytical procedure was validated according to the ICH guideline Q2 (R1) [34] with respect 
to selectivity, linearity, limits of quantification (LOQ), limit of detection (LOD), accuracy, precision 
(repeatability), and robustness (for details cf. supplementary material, Tables S4.1-S4.6). As 
shown in Figure 4.3, baseline separation of the parent compounds and the corresponding 
cleavage products was achieved.  
Figure 4.3: Representative chromatograms of 1 (A) and 7 (B) obtained after incubating the 
compounds in (A) phosphate buffer (pH 7.4) or (B) human plasma for 5 min. Fluorescence at an 
excitation wavelength of 330 nm and emission at 420 nm. 
Table 4.1: Retention factors (k) of the analytes 1-9 and the internal standard (IS), and selectivities 
(α) of the HPLC method. 
Compd. X k(X) 
Selectivitya 
α (X; Xa) α (X; 1) α (X; IS) α (Xa; IS) 
1 2.50 1.54 - 1.14 1.36 
2 2.88 1.47 1.15 1.31 1.12 
3 3.07 1.48 1.23 1.40 1.06 
4 1.89 1.58 1.32 1.16 1.83 
5 1.91 1.54 1.31 1.15 1.77 
6 1.98 1.61 1.26 1.11 1.79 
7 1.86 1.54 1.34 1.18 1.82 
 8b 2.01 1.50 1.24 1.09 1.64 
 9b 1.81 1.39 1.38 1.22 1.69 
IS 2.20 - - - - 
a Selectivities α calculated from the retention factors (k) of the parent compounds X (1-9), and 
the k values of the corresponding products of the first hydrolysis of the nitrogen mustard moiety 
Xa (1a – 9a, structures cf. Fig. 4.2), bendamustine (1) and the internal standard (IS) as indicated 
in parentheses. b Data provided by F. Antoni. 
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The retention factors (k) of 1-9 and of the 
internal standard, as well as the separation 
factors (α) are summarized in Table 4.1. 
Calibration curves (examples, cf. Figure 4.4) of 
the test compounds 1-9 and the internal 
standard in the concentration range between 
50 nM and 30 µM were linear with correlation 
coefficients r2 ≥ 0.996 for all test compounds 
(Table S4.1). The LOD and LOQ of compounds 
1-9 and the internal standard were calculated 
based on peak heights for a signal–to-noise 
ratio of 3:1 and 10:1, respectively. The LOD 
was in the range between 1.6 nM and 9.3 nM, 
and LOQ was between 5.4 nM and 31.2 nM 
(Table S4.2). Repeatability and accuracy were 
determined by analyzing three different 
concentrations within the specified range 
(250 nM – 10 µM) (Table S4.3). The relative standard deviation (RSD) was < 5% for all analytes 
and the accuracy was between 96.3% and 107.1%. Inter-day precision (coefficients of variation 
were ≤ 6.3%) was determined over a period of six months (Table S4.4). 
The method was demonstrated to be robust with respect to changes of flow rate (0.7 mL/min and 
0.8 mL/min), gradient (0 – 45% and 10 - 55% acetonitrile), pH of the mobile phase (pH 3 and 4), 
column temperature (25 °C and 35 °C), excitation and emission wavelengths (ex.: 320 nm, em: 
410 nm and ex: 340 nm, em: 430 nm) and duration of treatment with perchloric acid (1 M) for 
deproteination of BSA (50 mg/mL) containing solutions (Table S4.5, S4.6). The specificity and the 
baseline separation remained unaffected by varying mobile phase, flow rate and temperature. 
The peak areas were increased (up to approximately 12%) when the samples were treated with 
perchloric acid for 25 minutes compared to 15 minutes.  
 
 
 
 
 
 
Figure 4.4. Concentration-dependent intensity 
of the fluorescence signal of 1, 7 and the 
internal standard (IS) umbelliferon. Analytes 
were dissolved in acidic phosphate solution (pH 
2), prior to HPLC analysis. Excitation at 330 nm, 
emission at 420 nm. 
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Figure 4.5: Stability of 1, 4 and the internal standard (IS) umbelliferone. Conditions: Storage at 4 
°C in phosphate solution pH 2 for 24 hours (A) or in phosphate solution containing 0.5 M 
perchloric acid for 8 hours (B) to stop the hydrolysis of the nitrogen mustard group. Mean values 
± SEM (N = 3). 
 
The analytes were stable in 10 mM phosphate buffer 
(pH 2.0) over a period of 24 h, as shown in Figure 4.5 A 
for 1, 4 and umbelliferone as examples. We compared 
different deproteination procedures (acetonitrile, 2 M 
trichloroacetic acid, 2 M trichloroacetic acid in 
ethanol, 1 M perchloric acid) with regard to stability 
and recovery (Table 4.2) of the analytes. Treatment 
with 1 M ice-cold perchloric acid gave the best results. 
With respect to sample processing, stability of the 
analytes was guaranteed in the presence of 0.5 M 
perchloric acid over a period of 8 hours (examples cf. 
Figure 4.5 B). By contrast, in human and, especially, in 
murine plasma, the ester cleavage was too fast in case 
of 5-7 and 9 to determine the recovery of the intact 
compounds; considerable amounts degraded within 
seconds. 
 
  
Table 4.2: Recovery from human 
plasma (mean values ± SEM, n = 4) 
Compd. 
% Recovery from 
human plasma 
1 89.2 ± 0.7 
2 74.5 ± 2.9 
3 66.1 ± 1.6 
4 78.7 ± 4.0 
5 n. d.a 
6 n. d.a 
7 n. d.a 
 8b 55.4 ± 5.0 
 9b n. d.a 
IS 83.9 ± 1.6 
a Recovery not determined due to 
the short half-life. 
b Data provided by F. Antoni. 
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4.3.2 Stability in phosphate buffer (pH 7.4) 
The hydrolysis rate of the nitrogen mustard group of bendamustine, yielding hydrolysis product 
1a (Fig. 4.2) (4-{5-[(2-chloroethyl)(2-hydroxyethyl)amino]-1-methyl-1H-benzo[d]imidazol-2-
yl}butanoic acid) in the first and hydrolysis product 1b (Fig. 4.2) (4-{5-[bis(2-hydroxyethyl)amino]-
1-methyl-1H-benzo[d]imidazol-2-yl}butanoic acid) in the second step [24], is significantly reduced 
at low temperatures, at acidic pH values and high concentrations of chloride [13]. After incubation 
at physiological pH (phosphate buffer 10 mM, pH 
7.4, 37 °C), the samples were stored at 4 °C and at pH 
2.0 until HPLC-analysis to prevent further hydrolysis.  
As expected, the reactivity of the nitrogen mustard 
against nucleophiles, for instance water, was not 
affected by esterification of the carboxylic group in 
bendamustine. The hydrolysis of the parent 
compounds 1-7, resulting in the corresponding 
monohydroxy compounds 1a-7a occured at 
comparable rates with half-lives of about 10 min 
(Table 4.3).  
 
4.3.3 Stability in murine and human plasma 
Interestingly, in murine plasma the hydrolysis 
rate of the nitrogen mustard moiety in 
bendamustine was significantly lower (t½ = 35 
± 2.2 min) than in aqueous solution at 
physiological pH (t½ = 10.8 ± 2.9 min). By 
contrast, the ester moieties of 2-7, 
irrespective of the chemical nature of the 
substituents R, were prone to rapid cleavage 
(t½ < 2 min; cf. Table 4.4). Thus, in murine 
plasma the cleavage of the ester group in 2-7, 
resulting in bendamustine (1), was 
considerably faster than the hydrolysis of the 
nitrogen mustard moiety. 
Table 4.4: Half-lives of the esters 2-9, 
determined in murine and human plasma at 
37 °C (mean values ± SEM, n=3-4) 
 Half-life [min] 
Compd. Murine plasma Human plasma 
2 < 2 63.9 ± 8 
3 < 2 116.6 ± 9 
4 < 2 42.2 ± 2.7 
5 < 2 < 5 
6 < 2 < 5 
7 < 2 < 5 
 8b n. d. 39.9 ± 1.9 
 9b n. d. < 5 
  n. d.: not determined 
   b Data provided by F. Antoni. 
 
Table 4.3: Half-lives of compounds 1-7 
(hydrolysis of the nitrogen mustard 
group) in phosphate buffer (10 mM, pH 
7.4) at 37 °C (mean values ± SEM, n=3). 
Compd. Half-life [min]  
1 10.8 ± 2.9  
2 8.7 ± 1.4  
3 8.9 ± 1.4  
4 10 ± 1.0  
5 8.8 ± 1.0  
6 10.3 ± 1.3  
7 9.0 ± 1.7  
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Surprisingly, compounds 1-9 behaved differently in human compared to murine plasma. Firstly, 
the rate of the hydrolysis of the nitrogen mustard group was significantly slower in human plasma 
(1: t½ = 131 ± 10.2 min). Secondly, the chemical nature of the substituent R substantially 
determined the rates of ester cleavage (Table 4.4). Representative chromatograms of the 
decomposition in human plasma of compounds 2, 4, 7 and 8 are shown in Fig. 4.6.  
Figure 4.6. Representative chromatograms illustrating the different rates of decomposition of 
compounds 2 (A), 4 (B), 8 (C) and 7 (D; data provided by F. Antoni) after the incubation in human 
plasma at 37 °C for different periods of time. 
 
The sequence of degradation of the aminoalkyl esters 5, 6, 7 and 9, comprising unsubstituted 
ethylene (5-7) or trimethylene (9) chains, was the same as in murine plasma, yielding 
bendamustine as the first degradation product, due to rapid ester cleavage (t½ < 5 min, Table 4.4), 
followed by hydrolysis of the nitrogen mustard group.  
The neutral alkyl esters 2 (t½ = 63.9 ± 8 min) and 3 (t½ = 116.6 ± 9 min), the weakly basic 
morpholinoethyl (mofetil) ester 4 (t½ = 42.2 ± 2.7 min) and the branched, more basic pyrrolidino-
substituted ester 8 (t½ = 39.9 ± 1.9 min) showed considerably increased half-lives in human plasma 
compared to murine plasma (Table 4.4). The fast cleavage of 5, 6, 7 and 9, reminiscent of 
substrates of unspecific cholinesterases, in comparison to the retarded degradation of neutral, 
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less basic or branched esters (2, 3, 4 and 8) suggested an enzyme-mediated hydrolysis of the ester 
bond. Indeed, the inhibition of unspecific plasma esterases by physostigmine resulted in 
prolonged half-lives of compounds 4 and 5, which were investigated as examples. The effect of 
physostigmine was much more pronounced in case of the heterocyclic basic ester 5 (48.3 
compared to <5 min) than for the mofetil ester 4 (52.8 compared to 42.2 min) (Fig. 4.7). 
Figure 4.7. Decomposition of bendamustine mofetil ester 4 (A) and bendamustine 
pyrrolidinoethyl ester 5 (B) in human plasma at 37 °C in the presence (empty symbols) and the 
absence (filled symbols) of the esterase inhibitor physostigmine (100 µM). 
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4.3.4 Influence of protein concentration and esterase activity on the degradation of 
bendamustine esters 
The discrepancies between the decomposition kinetics of 1-7 in human and murine plasma 
supported the hypothesis that species-specific differences in protein content and esterase activity 
were associated with this phenomenon. Therefore, we determined the decomposition kinetics of 
1 and 4 as examples in the presence of both porcine liver esterase and different amounts of 
bovine serum albumin. The results revealed a significant correlation between the half-lives and 
the albumin concentration. The increase in the albumin concentration from 30 mg/mL to 50 
mg/mL led to the prolongation of the half-life by 42 % for compound 1 (t½ = 120.4 ± 7.0 min vs. t½ 
= 170.7 ± 14.2 min) and by 70% for compound 4 (t½ = 7.3 ± 1.3 vs. t½ = 12.4 ± 0.5) (Fig. 4.8). 
Figure 4.8: Decomposition of bendamustine 1 (A) and bendamustine mofetil ester 4 (B) in a 
solution of porcine liver esterase in phosphate buffer (pH 7.4) containing different concentrations 
(circles: 30 g/L; squares: 40 g/L; triangles: 50 g/L) of BSA. Compound 1 decomposed by hydrolysis 
of the nitrogen mustard moiety, whereas compound 4 primarily underwent ester cleavage to give 
1 under the conditions of this experiment (cf. Fig. 4.2). 
 
Additionally, the determination of the amounts of unspecific esterases revealed nearly 1.5 fold 
higher activity in murine plasma (6.04 ± 0.2 µmol·min-1·mL-1) compared to human plasma (4.26 ± 
0.23 µmol·min-1·mL-1). In this context it should be noted that the protein content of murine 
plasma (total protein: 40-60 g/L, albumin: 20-35 g/L [35]) is lower than that of human plasma 
(total protein: 64-83 g/L, albumin: 35-55 g/L [36]). The combination of both, the lower protein 
content and the higher esterase activity appear to be responsible for the considerably lower 
stability of bendamustine and esters of 1 in murine plasma. 
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4.4 Discussion 
Previously, solid phase extraction and mass spectrometric detection, requiring special equipment, 
were applied for the analysis of bendamustine in biological material [18, 37]. We aimed at 
establishing a simple, specific, sensitive and fast method to analyze esters of bendamustine (2-7) 
and the corresponding decomposition products, including 1, in aqueous solution and in biological 
material. Pencheva et al. (1: LOD 9.6 µg/mL, LOQ 34 µg/mL) [15] and Mathrusri Annapurna et al. 
(1: LOD 0.24 µg/mL, LOQ 0.73 µg/mL) [15] described HPLC methods using UV detection. Xie et al. 
[17] reported a more sensitive, convenient method for the determination of 1 and -hydroxy-
bendamustine in plasma, using perchloric acid for deproteination and fluorescence detection (1: 
LOD 5 ng/mL in plasma and urine). As the fluorescence-based method was most promising, we 
adapted this approach especially to the quantification of the new bendamustine esters and the 
corresponding hydrolysis products. Regarding the sensitivity and recovery of bendamustine, the 
modified HPLC procedure described here was comparable to the data reported by Xie et al. [17]. 
It should be stressed that, according to the optimized protocol, fluorescence detection allowed 
for the specific quantification of bendamustine derivatives with high signal-to-noise ratios despite 
protein precipitation with perchloric acid, which was reported unfavorable by 
Dubbelmann et al. [18]. 
Recently, several esters (2-7) of the cytostatic bendamustine (1) were demonstrated to be 
significantly more potent than the parent compound as cytostatic agents against a variety of 
human cancer cell types in vitro [29]. These results suggest that the antiproliferative activity has 
to be attributed to the derivatives on their own rather than to the conversion of the esters to 
bendamustine as the active principle. With respect to exploring the potential value as anticancer 
drugs in vivo, information on the stability of the esters in biological matrices are of utmost 
importance.  
The alkylating activity of nitrogen mustard derivatives such as 1-9 originates from the bis(2-
chloroethylamino) group, which is, apart from the reaction with bionucleophiles, a labile group, 
undergoing hydrolysis in solutions, especially at neutral or basic pH [13]. This reaction can be 
stopped by addition of acid, as demonstrated under the conditions of the HPLC analysis, when 
acidic phosphate solution was used as a component of the mobile phase, and perchloric acid and 
low temperature to precipitate plasma proteins. The established HPLC method enabled the 
analysis of the stability of 1 and corresponding neutral and basic esters in buffer, plasma, and 
against porcine liver esterase in the presence of different amounts of albumin.  
In buffer at pH 7.4 hydrolysis of the nitrogen mustard group was the prevailing reaction, occurring 
with comparable half-lives of around 10 min (1-7, Table 4.3). Interestingly, this decomposition 
reaction slowed down by a factor of up to 13 in the presence of plasma protein. This can be 
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explained by protection of the parent compounds in a hydrophobic environment when bound to 
albumin [38]. 
Due to different rates of hydrolysis of the ester and the nitrogen mustard moiety, the cleavage of 
the derivatives proved to be much more complex than that of 1. Cleavage of the ester group was 
slowest in case of the ethyl ester (3, t½ 116 min) followed by compounds 2 (t½ 64 min), 4 (t½ 42 
min) and 8 (t½ 40 min), i.e., in these cases the degradation kinetics was dominated by the 
hydrolysis of the nitrogen mustard moiety. These compounds having a more stable ester group 
(2, 3, 4 and 8) were converted to 1a (1b not determinable with this method) via bendamustine 
(1) and underwent hydrolysis at the nitrogen mustard moiety to give 2a, 3a, 4a, 8a as 
intermediates (examples cf. Fig. 4.6). By contrast, the cleavage of the ester bond was rapid (t½ <5 
min) in case of the 2-pyrrolidinoethyl (5), 2-piperidinoethyl (6), 2-(4-methylpiperazino)ethyl (7), 
and 3-pyrrolidinopropyl ester (9). For compounds such as 7, the corresponding hydrolysis product 
7a was not detectable due to very fast conversion to 1 (Fig. 4.2). It should be mentioned that 
unidentified reaction products were observed to a minor extent in the chromatograms (Fig. 4.6). 
Chemical reactions of the alkylating molecular species with bionucleophiles in the incubation 
mixture could have taken place, lowering the portion of residual analytes detectable with the 
applied method.  
The enzymatic hydrolysis in human plasma strongly depended on the presence or absence of a 
strongly basic group (cf. compds. 5-9) and on sterical hindrance (cf. compd. 8). These structural 
characteristics are reminiscent of substrates of unspecific cholinesterases [39]. Accordingly, the 
enzymatic cleavage was strongly inhibited by physostigmine in case of 5, but only slightly affected 
for the less basic ester 4. Interestingly, in contrast to human plasma, the same analytes were 
much less stable in murine plasma (t½ <2 min). These differences can be explained by the lower 
protein content and the higher enzymatic activity in murine compared to human plasma. The 
determination of the decomposition kinetics of 1 and 4 in presence of porcine liver esterase and 
different concentrations of bovine serum albumin (Fig. 4.8) revealed that the concentration of 
albumin had a significant effect on the hydrolytic stability of both, the nitrogen mustard and the 
ester bond. 
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4.5 Conclusion 
The properties of the introduced ester moieties define whether bendamustine esters are 
preferred substrates of unspecific plasma esterases and thus strongly determine the stability of 
the particular ester bond. The stabilization of bendamustine and esters by plasma proteins 
became obvious from the studies in the presence of different amounts of bovine serum albumin 
and from the investigations in murine and human plasma, which considerably differ regarding 
protein content. The activity of unspecific esterases was much higher in murine compared to 
human plasma. In concert, these species-dependent differences proved to cause tremendous 
discrepancies regarding the stability of the title compounds. This phenomenon has to be taken 
into account with respect to translational animal studies, and may also be relevant to 
pharmacological investigations of structurally diverse bioactive compounds other than 
cytostatics.  
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4.6 Supplementary material: Method validation 
Table S4.1: Slopes and intercepts of the equation y = a·x + b. Coefficients of determination (r2) 
calculated by simple linear regression from the data of three independent experiments. 
Compound a [µV·s·µM-1] b [µV·s] r2 
1   93570 ± 281.1  275.5 ± 941.2 0.9999 
2 103700 ± 572.3 -755.7 ± 1916 0.9997 
3  65030 ± 1107 -5786 ± 4702 0.9998 
4  23440 ± 1143  8122 ± 4899 0.9926 
5   45260 ± 782.8  2077 ± 3357 0.9983 
6  66850 ± 1286  7719 ± 5516 0.9963 
7   56700 ± 344.2 -2240 ± 1476 0.9994 
 8a   32990 ± 184.2  -2073 ± 794.5 0.9998 
 9a   35970 ± 146.1  -3619 ± 630.1 0.9999 
IS    69430 ± 218 -715.4 ± 1976 0.9994 
a Data provided by F. Antoni. 
 
  Table S4.2: Limit of detection (LOD) and 
quantification (LOQ) calculated with a signal 
to noise ratio of the peak heights of 3:1 and 
10:1, respectively. 
Compound LOD [nM] LOQ [nM] 
1 1.6 5.4 
2 2.4 7.9 
3 8.0 26.6 
4 9.3 31.2 
5 5.0 16.7 
6 4.8 16.1 
7 4.5 15.1 
 8a 5.0 16.5 
 9a 4.9 16.3 
IS 3.6 12.1 
a Data provided by F. Antoni. 
Table S4.4: Inter-day precision of 
the HPLC-method over a period of 6 
months. (Coefficient of variation (CV) 
in %, n = 6) 
Compound CV (%) 
1 2.37 
2 5.26 
3 3.14 
4 7.00 
5 3.58 
6 3.32 
7 4.46 
 8a 6.30 
 9a 4.73 
IS 4.91 
a Data provided by F. Antoni. 
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Table S4.3: Repeatability and accuracy of the HPLC-method. (n = 3-4) 
Compound 
Repeatability Accuracy [%] 
nominal 
concentration 
[µM] 
determined 
concentration ± 
SD [µM] 
RSD [%] 
95 % confidence 
intervall 
  
1 
10 10.03 ± 0.146 1.45 9.670 - 10.39 99.7 
1 1.079 ± 0.018 1.63 1.035 - 1.122 92.7 
0.25 0.273 ± 0.016 5.77 0.234 - 0.312 91.7 
2 
10 9.948 ± 0.214 2.15 9.417 - 10.48 100.5 
1 1.134 ± 0.065 5.71 0.973 - 1.294 88.2 
0.25 0.243 ± 0.008 3.32 0.223 - 0.263 102.7 
3 
10 10.05 ± 0.071 0.71 8.195 - 11.31 99.5 
1 1.017 ± 0.031 3.06 0.861 - 1.097 98.3 
0.25 0.238 ± 0.007 2.76 0.215 - 0.252 105.0 
4 
10 9.750 ± 0.626 6.42 8.195 - 11.31 102.6 
1 0.979 ± 0.047 4.84 0.861 - 1.097 102.1 
0.25 0.234 ± 0.001 3.25 0.215 - 0.252 107.1 
5 
10 9.910 ± 0.202 2.04 9.410 - 10.41 100.9 
1 0.983 ± 0.055 5.61 0.846 - 1.120 101.7 
0.25 0.254 ± 0.011 4.18 0.228 - 0.280 98.4 
6 
10 9.885 ± 0.177 1.79 9.440 - 10.33 101.2 
1 1.024 ± 0.045 4.37 0.913 - 1.135 97.7 
0.25 0.243 ± 0.012 4.97 0.213 - 0.273 102.8 
7 
10 9.893 ± 0.142 1.43 9.540 - 10.24 101.1 
1 0.916 ± 0.027 2.93 0.849 - 0.983 109.2 
0.25 0.256 ± 0.011 4.17 0.229 - 0.282 97.7 
 8a 
10 9.918 ± 0.450 4.54 8.800 - 11.04 100.8 
1 0.974 ± 0.012 1.23 0.944 - 1.004 102.7 
0.25 0.244 ± 0.001 0.21 0.243 - 0.245 102.5 
 9a 
10 10.38 ± 0.283 2.73 9.674 - 11.08 96.3 
1     0.995 ± 0.01 0.98 0.972 - 1.020 100.5 
0.25     0.256 ± 0.01 2.84 0.238 - 0.273 97.7 
IS 
10 10.05 ± 0.143 1.42 9.700 - 10.41 99.5 
1 0.987 ± 0.015 1.52 0.950 - 1.025 101.3 
0.25 0.256 ± 0.012 4.84 0.225 - 0.286 97.7 
a Data provided by F. Antoni. 
 
 
 
  
 Table S4.5: Effect of the flow rate, the composition and the pH of the mobile phase and the column temperature on the retention factors 
relative to the respective retention factors of the optimized method (100%).  
Compound  Flow rate  Gradient a)  pH = 4  Temperature 
 0.7 mL/min 0.8 mL/min  0 - 45% MeCN 10 - 55% MeCN    25 °C 35 °C 
1b   96.64 104.80   80.85 81.35   100.44   102.79 98.38 
1  94.72 105.39  76.85 100.40  101.64  101.36 100.16 
2  94.77 105.54  73.12 102.00  105.24  101.16 100.45 
4  94.72 105.43  77.61 96.59  112.31  101.41 99.97 
IS   95.66 104.31   78.07 99.12   100.72   102.53 98.74 
a) MeCN = acetonitrile 
 
Table S4.6: Effects of the flow rate, the composition and the pH of the mobile phase, the column temperature, the wavelengths and the 
duration of treatment with perchloric acid on the peak areas relative to the respective peak areas of the optimized method (100%). 
Compound  Flow rate  Gradient a)  pH = 4  Temperature  Wavelengths b)  Incubation period c) 
 0.7  
mL/min 
0.8  
mL/min 
 0-45 % 
MeCN 
10-55 % 
MeCN 
   25 °C 35 °C  λex: 320  
λem: 410 
λex: 340  
λem: 430 
 15 min 25 min 
1b   100.24 97.29   109.00 99.35   106.52   100.25 98.15   69.47 113.42   102.30 107.62 
1  107.07 94.43  96.78 101.97  103.10  98.82 99.06  90.40 79.87  99.57 114.93 
2  108.44 94.12  102.05 101.11  100.23  98.92 99.03  89.96 80.33  102.21 115.63 
4  107.22 92.00  97.32 97.57  102.67  98.58 97.87  88.09 82.48  101.16 114.86 
IS   106.91 96.08   101.15 99.39   101.53   97.01 99.17   46.59 156.49   100.50 113.30 
a) MeCN = acetonitrile; b) λex: excitation wavelength, λem: emission wavelength; c) Incubation period for deproteination of BSA (50 
mg/mL) containing solutions with perchloric acid (1 M). 
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5 Chapter V 
Esters of bendamustine are by far more 
potent cytotoxic agents than the parent 
compound against human sarcoma and 
carcinoma cells 
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5.1 Introduction 
The alkylating agent bendamustine (1, Fig. 5.1) was synthesized in 1963 [1, 2] and developed as 
an anticancer drug in the German Democratic Republic [3-5]. In the 1990s bendamustine got into 
the focus of research again [6]. It is approved for the treatment of chronic lymphocytic leukemia 
(CLL) [7, 8], indolent non-Hodgkin lymphoma (NHL) [9] and multiple myeloma (MM) [10, 11] or as 
second line therapy of refractory diseases [12-14] in various countries. Current clinical trials 
suggest beneficial effects in the treatment of solid cancer types such as breast cancer [15] or 
small-cell lung cancer [16]. Most treatment regimens include bendamustine in combination with 
other anticancer drugs including biologicals [17-20], for instance rituximab [17, 19, 20]. It has 
been hypothesized that, apart from the alkylating nitrogen mustard group (N-Lost), the 
benzimidazole scaffold may contribute to the antitumor activity for instance, due to 
antimetabolite properties, by facilitating nuclear transport or inhibiting DNA repair [6]. Besides 
the alkylation of DNA, causing strand breaks, bendamustine induces the expression of p53 [21], 
triggers apoptosis [22] and down-regulates mitotic checkpoints, leading to mitotic catastrophe 
[23, 24]. Recent patent applications aimed at formulations for oral administration [25-27]. Alkyl 
(C1 – C24) esters of bendamustine were reported as potential prodrugs for intravenous application 
[28], and biodegradable polyphosphoesters were described as an approach to stabilize 
bendamustine in solution [29]. Another approach aimed at increasing the cytotoxicity by 
constructing dimeric and dendrimeric bendamustine derivatives [30].  
Figure 5.1: Structures of bendamustine (1) and the bendamustine esters 2-7. 
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Exploring the properties of derivatives of bendamustine (1), esters of bendamustine (2-7, Fig. 5.1) 
[31] comprising basic moieties (4-7) were prepared as potential prodrugs with higher solubility 
compared to simple esters such as compounds 2 and 3, which were mainly prepared as synthetic 
intermediates [32, 33]. Very recently, we reported on the stability of the nitrogen mustard and 
the ester moieties in compounds 2-7 against hydrolysis and enzymatic cleavage in buffer, in the 
presence of porcine butyrylcholine esterase as well as in human and murine plasma [34]. The 
moderately basic morpholinoethyl ester (4) proved to be of particular interest with respect to 
both solubility and stability [34]. Preliminary data suggested considerably increased cytotoxicity 
of the esters compared to the parent compound 1, the basic compounds being of particular 
interest [31]. Based on the assumption that higher antiproliferative activity may result from 
increased cellular accumulation, additional mechanisms of action or both, we compared 
compounds 2-7 with bendamustine (1) regarding cytotoxicity against a panel of human sarcoma 
and carcinoma cell types, representing hematologic and solid malignancies. Additionally, the 
induction of p53 expression and apoptosis, cellular enrichment and the involvement of the 
organic cation transporters OCT1 and OCT3 were investigated.  
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5.2 Material and Methods 
5.2.1 Ethics Statement 
Human embryonal kidney (HEK293) cells were purchased from the German Collection of 
Microorganism and Cell Cultures (DSMZ, Braunschweig, Germany). Cancer cell lines were 
obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA): SK-MEL-3 
(malignant melanoma; HTB-69), Capan-1 (pancreatic adenocarcinoma; HTB-79), HT-29 (colorectal 
adenocarcinoma; HTB-38), SK-ES-1 (Ewing´s sarcoma; HTB-86), HEL92.1.7 (erythroleukemia; TIB-
180), Jurkat (acute T-cell leukemia; TIB-152), U-937 (histiocytic lymphoma; CRL-1593.2), LNCaP 
(prostate cancer; CRL-1740) and NCI-H460 (large cell lung cancer; HTB-177), and MG-63 
(osteosarcoma; CRL-1427) cells. 
 
5.2.2 Chemicals and reagents 
Bendamustine hydrochloride (1) and the esters 2-7 were kindly provided by Arevipharma 
(Radebeul, Germany). Stock and working solutions of 1-7 were prepared in dimethylsulfoxide 
(DMSO). Thiazolyl blue tetrazolium bromide (MTT), umbelliferone, 4-[4-(dimethylamino)styryl]-
N-methylpyridinium iodide (ASP+), penicillin-streptomycin and tetrapentyl ammonium (TPA) were 
from Sigma (Taufkirchen, Germany). Hygromycin B was from A.G. Scientific, (San Diego, CA, USA). 
Fetal calf serum (FCS) was from Biochrom (Berlin, Germany). A 1 mM stock solution of TPA was 
prepared in phosphate buffered saline (PBS). The 100 µM stock solution of ASP+ was prepared in 
PBS containing 10 % DMSO. HPLC-grade acetonitrile was from Fisher Scientific (Schwerte, 
Germany). Demineralized water was prepared with a Milli-Q system (Merck; Schwalbach, 
Germany). If not otherwise stated, all other reagents were of analytical grade and purchased from 
Sigma (Taufkirchen, Germany).  
 
5.2.3 Cell culture  
Cancer cells: All media were from Sigma (Taufkirchen, Germany) and supplemented with 10 % 
FCS. SK-MEL-3, Capan-1, HT-29 and SK-ES-1 cells were cultured in McCoy´s 5A medium, 
supplemented with 2.2 g/L NaHCO3 (Merck, Darmstadt, Germany). HEL92.1.7, Jurkat, U-937, 
LNCaP and NCI-H460 were cultured in RPMI-1640 containing 110 mg/L sodium pyruvate, 10 mM 
HEPES (both from Serva, Heidelberg, Germany) and 2.0 g/L NaHCO3. MG-63 cells were cultured 
in EMEM supplemented with 2.2 g/L NaHCO3. Genetically modified HEK293 cells: Transfected 
human embryonic kidney cells (HEK293) were cultured in EMEM, supplemented with 
penicillin/streptomycin (100 U/mL / 100 µg/mL) and 250 µg/mL hygromycin B. The cells were 
cultured in a water-saturated atmosphere with 5 % CO2 at 37 °C and passaged once to twice a 
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week. Adherently growing cells were treated with trypsin/EDTA (0.5 mg/mL / 0.22 mg/mL) (PAA, 
Pasching, Austria) and washed with medium prior to transfer into new culture flasks. Cells 
growing in suspension were passaged after mechanical separation of cell agglomerates. 
 
5.2.3.1 HEK293 cells expressing the human organic cation transporters OCT1 or OCT3  
Parental HEK293 cells were transfected with the plasmid pcDNA3.1/Hygro(-)-OCT1, containing 
the full length SLC22A1 cDNA (NM_003057) encoding the human OCT1 protein, as described [35]. 
After hygromycin selection, single colonies were characterized for SLC22A1 mRNA expression by 
real-time qRT-PCR, and the cell clone with the highest expression was further analyzed with 
respect to protein expression and [3H]-1-methyl-4-phenylpyridinium ([3H]MPP+) uptake (cf. 
Supporting Information). HEK-Co cells (control) were established by the same method using the 
empty plasmid pcDNA3.1/Hy(-) for transfection [36] (characterization of HEK-OCT1 and HEK-Co 
cells cf. Supporting Information Fig. S5.1). HEK-OCT3 cells were recently described [37]. HEK-Co, 
HEK-OCT1 and HEK-OCT3 cells were provided by Prof. Dr. Jörg König. 
 
5.2.4 Chemosensitivity assays 
Depending on the characteristics of the cells, two different assays were performed. For 
adherently growing cells (HT-29, NCI-H460, SK-MEL-3, MG-63, Capan-1), cytotoxic and cytocidal 
effects were determined in the crystal violet assay [38], whereas for loosely adherent cells 
(LNCaP, SK-ES-1) and cells growing in suspension (HEL 92.1.7, Jurkat, U-937) the MTT-assay [39] 
was used with minor modifications [38]. In brief, 1.5 · 103 (HT-29, NCI-H460, SK-MEL-3, MG-63, 
Capan-1) or 5 · 103 (Jurkat, U-937, HEL92.1.7, LNCaP, SK-ES-1) cells per well were seeded into flat-
bottom 96-well plates (Sarstedt, Nümbrecht, Germany).  All compounds were used as solutions 
prepared in DMSO (final concentration of DMSO in the assays: 0.1 %) and tested at final 
concentrations (8 replicates per concentration) of 1, 3, 10, 30 and 50 µM. Absorbance was 
measured at 580 nm in a 96-well plate reader (GENios pro microplate reader, Tecan, Salzburg, 
Austria). Effects were quantified as previously described [40] for both assays.  
In addition to long-term exposure, IC50 values were determined after an incubation period of 96 
hours, following the same procedure as described above (4 instead of 8 replicates). As suggested 
by the National Cancer Institute [41] the corrected T/C values (T/Ccorr) were plotted against the 
logarithm of the concentrations, and the IC50 values were calculated using Prism 5.01 (GraphPad 
Software, La Jolla, CA, USA) according to the “log (inhibitor) vs. normalized response-variable 
slope” equation.  
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5.2.5 Detection of apoptosis (annexin V/propidium iodide assay)  
Apoptosis was determined by incubating progrediently growing Jurkat cells with medium 
containing 1, 2, 4 or 5 at a concentration of 10 µM or 0.1 % of DMSO (untreated control). After 
different periods of incubation (6, 24, 48 hours), samples were analyzed using the Annexin V-FITC 
apoptosis detection kit l (BD Biosciences, Heidelberg, Germany) according to the manufacturer’s 
protocol using 106 cells/mL. Cells were analyzed using a FACSCalibur flow cytometer 
(BD Biosciences, Heidelberg, Germany). The compensation was performed for each experiment 
with annexin V-FITC (530/30 BP filter) and propidium iodide (585/42 BP filter), respectively. At 
least 1 · 104 events were registered per sample and debris as well as cell aggregates were excluded 
by forward (FSC) versus side scatter (SSC) gates. Raw data were analyzed using FlowJo V10 
software (Treestar Inc., Ashland, OR, USA). 
 
5.2.6 Detection of p53 expression by immunoblotting 
The expression of the tumor suppressor p53 by NCI-H460 and HT-29 cells was determined after 
incubating the cells with compounds 1, 2, 4 and 5 at different concentrations for 24 hours. The 
cells (from a 10-cm culture dish, 70 % confluency) were washed twice with PBS and harvested by 
scraping after addition of ice-cold buffer A (10 mM HEPES pH = 7.9, 10 mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA, protease inhibitor mix (Sigma-Aldrich)). After adding Nonidet P-40 (NP-40) (Sigma, 
Taufkirchen, Germany) to a final concentration of 1 %, the cell suspensions were vortexed and 
subsequently centrifuged at 13000 g and 4 °C for 30 seconds. The pellets were re-suspended in 
buffer B (buffer A + 400 mM NaCl, 1% NP-40) and gently agitated using a Sarmix M2000 (Sarstedt, 
Nümbrecht, Germany) at 4 °C for 15 min, followed by centrifugation (13000 g, 4 °C, 5 min; 
Microfuge; Eppendorf, Hamburg, Germany). The concentration of soluble protein was 
determined according to Bradford using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Munich, 
Germany). An amount of 30 µg total protein of each sample and 8 µL of a biotinylated molecular 
weight standard (1:6 dilution) (Cell Signaling, Danvers, MA, USA) was separated by SDS-PAGE 
(12 % gel) and afterwards electroblotted (150 V, 30 min) to nitrocellulose membrane (Peqlab, 
Erlangen, Germany). The blot was incubated with anti-p53 rabbit mAb (dilution 1:1000) (Cell 
Signaling) and anti-histone H2B Ab (dilution 1:1000) (Cell Signaling) as loading control. The 
primary antibodies and the “protein ladder” were simultaneously detected with a horseradish 
peroxidase (HRP)-coupled donkey anti rabbit mAb (dilution 1:1000) (Santa Cruz biotechnology, 
Heidelberg, Germany) or the anti-biotin HRP-coupled antibody (dilution 1:5000) (Cell Signaling), 
respectively. The bands were detected by bioluminescence using the Pierce ECL Western Blotting 
Substrate (Thermo Scientific, Dreieich, Germany). After exposure, the x-ray film (Amersham 
Hyperfilm™ ECL, GE Healthcare, München, Germany) was developed (CAWOMAT 2000 IR, CAWO, 
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Schrobenhausen, Germany) and analyzed using a GS-710 imaging densitometer and Quantity One 
V. 4 software (Bio-Rad Laboratories, Munich, Germany).  
 
5.2.7 Quantification of cell-associated bendamustine and derivatives 
Accumulation of bendamustine and selected bendamustine esters by HT-29 and NCI-H460 cells 
was determined by HPLC. For this purpose, 1.5 · 106 cells/well were seeded into 6-well plates 
(Sarstedt, Nümbrecht, Germany). After two days of cultivation, the cells were incubated in PBS 
containing 30 µM of 1, 2, 4 or 5 and 200 µM of umbelliferone as internal standard at 37 °C for 
10 minutes. After removing the medium, the cells were washed three times with PBS. Untreated 
cells were detached with trypsin/EDTA and counted. The treated cells were harvested by adding 
200 µL of ice-cold perchloric acid (1 M) and scraping. Subsequently, the samples were vortexed 
and sonicated (Branson 3200 ultrasonic cleaner; Branson, Danbury, USA) for 10 minutes. After 
5 minutes of centrifugation (13000 g, 4 °C), the supernatants were filtered (0.2 µm Phenex; 
Phenomenex, Aschaffenburg, Germany) and directly analyzed by HPLC with fluorescence 
detection according to a recently reported validated procedure [34]. The normalization of the 
measured concentration to the cell count allowed for a calculation of the cell-associated amount 
of the respective test compound. Additionally, the ratio of cell-associated substance compared to 
the applied concentration (30 µM) was calculated based on an average cell volume of 3 pL.  
 
5.2.8 Flow cytometric determination of OCT1 and OCT3 activity  
The previously described fluorescent substrate of organic cation transporters, 4-(4-
dimethylaminostyryl)-N-methylpyridinium (ASP+) [42-45], was used to determine the function of 
OCT1 and OCT3 by flow cytometry in the absence and the presence of bendamustine and selected 
bendamustine esters. HEK293 cells expressing the transporter of interest were trypsinized and 
washed twice with PBS, prior to re-suspension of 0.5 · 106 cells in 500 µL of PBS containing 
2 % (v/v) FCS. The cells were incubated with ASP+ (100 µM stock solution in PBS containing 10 % 
DMSO) for 5 minutes, allowing for cellular accumulation, and subsequently analyzed with a 
FACSCalibur flow cytometer. ASP+ was excited at 488 nm and the fluorescence was measured 
using a 530/30 nm and a 585/42 band-pass filter. At least 1 · 104 single cells were analyzed by 
appropriate FSC/SSC gating.  
For the determination of Km, cell suspensions of HEK-OCT1 and HEK-OCT3 cells as well as HEK-Co 
cells as control for unspecific uptake of ASP+ were incubated with ASP+ at increasing 
concentrations at 37 °C for 5 minutes. Subsequently, two volumes of an ice-cold 200 µM solution 
of the standard inhibitor tetrapentyl ammonium (TPA) [46-48] in PBS/FCS were added to one 
volume of cell suspension. The mixture was immediately analyzed. The mean fluorescence 
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intensities (MFI) were calculated using FlowJo V10, and the difference between total (HEK-OCT1 
or HEK-OCT3 cells) and unspecific (HEK-Co cells) uptake was plotted as specific uptake against the 
concentration of ASP+. The linearity of ASP+ uptake (1 µM) at 37 °C was assessed between 
30 seconds and 7 (HEK-OCT1) respectively 9 (HEK-OCT3) minutes. Km was calculated (GraphPad 
Prism 5.01) using the Michaelis-Menten equation.  
The inhibition of ASP+ uptake was measured to determine the IC50 values of TPA and compounds 
1, 2, 4 and 5. The cells were pre-incubated with the respective test compound at different 
concentrations at room temperature for 10 minutes. Afterwards, ASP+ was added to a final 
concentration of 1 µM, and the samples were incubated at 37 °C in the dark for 5 minutes. 
Subsequently, the cells were washed, re-suspended in ice-cold PBS/FCS and stored on ice in the 
dark until measurement. The normalized mean fluorescence intensities of the OCT expressing 
cells, set to 100 % in the absence of an inhibitor, were calculated by subtracting the mean 
fluorescence intensity of unspecific ASP+ uptake into HEK-Co control cells. The normalized 
fluorescence intensities in the presence of an inhibitor were plotted against the logarithm of the 
concentrations of the test compounds to calculate IC50 values. The “log (inhibitor) vs. normalized 
response-variable slope” equation of GraphPad Prism 5.01 was used for this purpose. 
 
5.2.9 Imaging of cellular ASP+ uptake by confocal laser scanning microscopy  
HEK-Co, HEK-OCT1 and HEK-OCT3 cells were seeded into 8-well µ-Slides (Ibidi, Munich, Germany) 
(2 · 104 cells/well) and allowed to attach for 48 hours. Prior to the staining procedure, the medium 
was replaced by PBS and the DNA probe Draq5 (5 µM) (Biostatus, Shepshed, UK) was added to 
each well. To monitor the inhibition of ASP+ uptake, 200 µM of TPA or 15 µM of compound 5, 
respectively, were added and incubated at 37 °C for 5 minutes. Subsequently, ASP+ was added to 
reach a concentration of 1 µM, and the cells were incubated for 5 minutes in the dark. Imaging 
was performed with an Axiovert 200 M confocal microscope coupled to a Zeiss LSM 510 scanning 
device (Carl Zeiss, Oberkochen, Germany) using a Plan-Apochromat 63x/1.40 oil immersion 
objective. Draq5 was excited at 633 nm and fluorescence was detected using a 650 nm long-pass 
filter, ASP+ was excited at 488 nm and detected using a 565/35 nm band-pass filter. 
 
5.2.10  Determination of OCT1 and OCT3 expression by various cancer cells  
The expression of SLC22A1 and SLC22A3 mRNA in different cancer cell types was analyzed by 
quantitative RT-PCR using the Roche LightCycler system. Total RNA was isolated using the 
NucleoSpin RNA Purification Kit (Macherey-Nagel, Dueren, Germany) according to the 
manufacturer’s instructions. One µg of total RNA was reversely transcribed using the iScript Kit 
(Biorad, Munich, Germany) according to the manufacturer´s instructions. SLC22A1, SLC22A3 and 
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-actin mRNA levels were determined using the LightCycler System and the FastStart DNA Master 
SYBR Green I Kit (both from Roche, Mannheim, Germany). The primer pair for the amplification 
of the SLC22A1 cDNA fragment was oOCT1-RT.for (CTGCCTGGTGAATGCTGAGC) and oOCT1-
RT.rev (ACATCTCTCTCAGGTGCCCG), for the SLC22A3 cDNA fragment oOCT3-RT.for 
(CAAGCAATATAGTGGCAGGGG) and oOCT3-RT.rev (CCTCAAAGGTGAGAGCGGGA) and for the -
actin fragment oActin.for (TGACGGGGTCACCACACACTGTGTGCCCATCTA) and oActin.rev 
(CTAGAAGCATTTGCGGTGGACGATGGAGGG). PCR was performed according to the 
manufacturer´s instructions with 0.5 µM of the respective sense and antisense primers, 4 mM 
MgCl2 and 1-fold FastStart DNA Master SYBR green I mix in a total volume of 20 µL including 1 µL 
of the synthesized sscDNA. Cycling conditions were as follows: 10 min denaturation at 94 °C, 
followed by 45 cycles of 10 s denaturation at 94 °C, 15 s primer annealing at 64 °C and 30 s of 
elongation at 72 °C. The amount of -actin, SLC22A1 and SLC22A3 cDNAs were determined using 
a serial plasmid dilution (pOCT1.31; from 106 to 104 fg) as amplification standard. The -actin 
concentration, calculated in relation to the standard curve, was set to 100 % and the respective 
SLC22A1 and SLC22A3 mRNA values are given as a percentage of -actin amplification.  
 
5.2.11  Western blot analysis of hOCT1 expression 
HEK-Co and HEK-OCT1 cells were lysed with 0.2% ice-cold SDS containing protease inhibitor 
mixture (Mini-complete protease inhibitor cocktail tablets; Roche Diagnostics-Applied Science, 
Mannheim, Germany). Protein concentration of each lysate was measured with a bicinchoninic 
acid assay (BCA protein assay kit, Thermo Fisher Scientific, Waltham, MA, USA). 20 µg of cell 
lysates were subjected to a 10% SDS-polyacrylamide gel electrophoresis under reducing 
conditions. Separated proteins were transferred onto nitrocellulose membranes (Protran 
nitrocellulose transfer membrane; Whatman, Dassel, Germany). Blots were probed with the KEN 
antiserum (1:10000) directed against human OCT1 [49] overnight at 4 °C. Membranes were then 
incubated with a horseradish peroxidase-conjugated goat-anti-rabbit secondary antibody 
(1:10 000; Sigma Aldrich, Munich, Germany). Immunoreactive bands were visualized using an ECL 
western blotting detection reagent (GE Healthcare, Buckinghamshire, UK) and a Chemidoc XRS 
imaging system (Bio-Rad, Munich, Germany). To control sample loading, membranes were 
incubated for 30 min with restore western blot stripping buffer (Pierce, Rockford, USA) at 37 °C 
and reprobed with a mouse monoclonal anti-human β-actin antibody (1:10000; Sigma Aldrich, 
Munich, Germany). A horseradish peroxidase-conjugated goat-anti-mouse antibody 
(GE Healthcare Europe, Freiburg, Germany) was used as secondary antibody (dilution 1:4000). 
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5.2.12   Immunofluorescence detection of hOCT1 expression 
The cellular localization of the OCT1 protein in the stably transfected HEK-OCT1 cells was analyzed 
by immunofluorescent staining. The OCT1-specific KEN antiserum was used at a dilution of 
1:1000. Subsequently, cells were incubated with an Alexa Fluor 488 conjugated goat-anti-rabbit 
secondary antibody (1:10,000; Invitrogen, Carlsbad, CA). 
 
5.2.13  [3H]MPP+ transport assay  
HEK-OCT1 and HEK-Co cells were seeded in poly-D-lysine (Sigma Aldrich, Taufkirchen, Germany) 
coated 48-well plates at a density of 1.2 · 105 cells/well. After incubation at 37 °C and 5% CO2 for 
48 h medium was replaced by warm (37 °C) uptake buffer (142 mM NaCl, 5 mM KCl, 1 mM K2HPO4, 
1.2 mM MgSO4, 1.5 mM CaCl2, 5 mM glucose and 12.5 mM HEPES, pH 7.3). The uptake assay was 
started by addition of [3H]MPP+ (80 Ci/mmol, American Radiolabeled Chemicals, St Louis, MO) at 
indicated concentrations (concentration dependency) or at a concentration of 50 µM (time 
dependency). Cells were incubated at 37 °C for 3 min (concentration dependency) or at indicated 
time points (time dependency). Uptake was stopped by washing the cells three times with ice-
cold uptake buffer. Afterwards, cells were lysed with 5 mM Tris buffer (pH 7.3) containing 0.1% 
Triton X-100. The intracellular accumulation of radioactivity was determined by liquid scintillation 
counting (PerkinElmer, Rodgau-Jügesheim, Germany) and protein concentration of each lysate 
was measured with the BCA assay. We performed two experiments each on two different days (n 
= 4). The OCT1-mediated net uptake of [3H]MPP+ was determined as the difference in substrate 
uptake between HEK-OCT1 and HEK-Co cells. Data were presented as means ± standard error of 
the mean. A value of p < 0.05 was considered statistically significant.  
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5.3 Results and discussion 
5.3.1 Cytotoxicity of bendamustine and derivatives 
The cytotoxicity of compounds 1-7 against tumor cells was determined both as an end point and 
kinetically. IC50 values of compounds 1-7 (Table 5.1 and Fig. S5.2) were calculated after 96 hours 
of incubation and the cytotoxic drug effect was measured over a period of 5 days (Fig. 5.2 and 
Supplementary Material, Fig. S5.3 – S5.12). The kinetic approach allows the distinction between 
cytotoxic, cytostatic and cytocidal drug effects [40].  
 
Table 5.1: Cytotoxicity of compounds 1-7 against different human tumor cell lines, expressed as 
IC50 values (µM) after 96 hours of incubation.  
Cell line 
Compound 
1 2 3 4 5 6 7 
HEL 92.1.7 b 86.2 ± 2.6 2.52 ± 0.09 2.85 ± 0.02 2.35 ± 1.02 1.04 ± 0.01 1.29 ± 0.01 1.72 ± 0.04 
Jurkat b 43.4 ± 4.8 3.14 ± 0.11 3.84 ± 0.04 3.19 ± 1.01 0.61 ± 0.02 0.83 ± 0.01 0.90 ± 0.03 
U-937 b 83.4 ± 8.5 1.83 ± 0.01 1.94 ± 0.01 3.2 ± 0.96 0.83 ± 0.19 1.08 ± 0.20 1.28 ± 0.28 
MG-63 a 55.8 ± 1.90 1.85 ± 0.05 2.14 ± 0.06 3.45 ± 0.06 0.38 ± 0.06 0.53 ± 0.01 0.55 ± 0.01 
SK-ES1 b 9.6 ± 0.3 0.18 ± 0.02 0.18 ± 0.01 0.91 ± 0.08 0.09 ± 0.01 0.19 ± 0.01  0.19 ± 0.03 
Capan-1a 18.9 ± 4.5 0.60 ± 0.04 1.00 ± 0.01 1.38 ± 0.01 0.12 ± 0.02 0.17 ± 0.01 0.25 ± 0.02 
LNCaP b 77.9 ± 5.6 0.95 ± 0.15 1.52 ± 0.05 2.2 ± 0.1 0.50 ± 0.08 0.75 ± 0.03 0.93 ± 0.12 
NCI-H460 a 90.0 ± 4.3 4.82 ± 0.03 4.80 ± 0.01 9.65 ± 1.27 0.90 ± 0.01 1.17 ± 0.02 1.24 ± 0.06 
HT-29 a > 100c 9.35 ± 0.04 10.0 ± 0.10 8.99 ± 0.47 1.17 ± 0.06 1.71 ± 0.01 2.35 ± 0.01 
SK-Mel3 a > 100c 13.8 ± 0.4 21.7 ± 4.10 20.9 ± 0.9 0.83 ± 0.18 1.24 ± 0.07   1.0 ± 0.27 
Data are mean values ± SEM of 3 independent assays with 4 replicates per compound concentration. 
a) Crystal violet assay  
b) MTT-assay  
c) Mean value ± SEM of 2 independent assays 
 
Although 1 is approved for hematologic malignancies (sarcoma), the effects on representative 
tumor entities were rather weak (Table 5.1, Fig. 5.2 and Supporting Information). The IC50 values 
were > 80 µM against HEL 92.1.7 (erythroleukemia) and U-937 (histiocytic lymphoma), and 43 µM 
against Jurkat cells (acute T-cell leukemia, Fig. 5.2A). By contrast, the Ewing´s sarcoma cells SK-
ES-1 showed a distinct response upon treatment with bendamustine (IC50 ~ 10 µM; Table 5.1, Fig. 
5.2B), whereas the chemosensitivity of MG-63 osteosarcoma cells was markedly lower 
(IC50 ~ 56 µM) with cytocidal drug effects at concentrations above 30 µM (Fig. S5.6). Surprisingly, 
with an IC50 value < 20 µM Capan-1 pancreatic cancer cells showed moderate chemosensitivity. 
On the contrary, 1 was ineffective (SK-MEL-3 melanoma, HT-29 colorectal carcinoma) or only very 
weakly active (LNCaP prostate cancer; NCI-H460 large cell lung cancer) against the other 
carcinoma cell types (IC50 values 78 to > 100 µM).  
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Figure 5.2: Antiproliferative activity of compounds 1, 4 and 5 against selected sarcoma and 
carcinoma cells upon long-term incubation. Jurkat (A; acute T cell leukemia), SK-ES-1 (B; Ewing´s 
sarcoma), NCI-H460 (C; large cell lung cancer) and HT-29 (D; colorectal cancer) cells were treated 
with compounds 1, 4 and 5 at concentrations between 1 µM and 50 µM over an incubation period 
of 5 days. Antiproliferative and cytocidal effects correspond to the left y-axes. The growth curves 
of untreated control cells (open circles) correspond to the right y-axes. Data are mean values ± 
SEM of at least 2 independent assays with 8 replicates per compound concentration. 
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In contrast to the parent compound bendamustine, the derivatives 2-7 exhibited considerably 
higher potencies up to factors > 100 both, against the sarcoma and the carcinoma cells 
investigated. With respect to the cytotoxic effects, compounds 2-7 fall into two groups: the alkyl 
esters (2, 3) and the mofetil ester 4 on one hand, and the basic heterocyclic esters 5-7 on the 
other hand. Compared to bendamustine, compounds 2-4 showed a 10- to 30-fold increase in 
potency, and 5-7 were 60- to 120-fold more potent than 1.  
Compounds 2-4: Among compounds 2-4, minor differences were observed at SK-ES-1 and 
NCI-H460 cells (Table 5.1) with a more pronounced effect of the alkyl esters 2 and 3 against 
SK-ES-1 cells (IC50 values: 2 and 3: ~ 0.2 µM, 4: 0.9 µM). The increase in toxicity compared to 1 
was most striking at HEL92.1.7, LNCaP, MG-63 and, in case of the alkyl esters 2 and 3, at SK-ES-1 
cells. Comparable IC50 values of 2-4 were confirmed by the cytotoxic drug effects over a period of 
5 days (Fig. S5.3-S5.12). Compounds 2-4 revealed cytocidal effects at all investigated cancer cell 
types at concentrations of 30 and 50 µM, except for SK-MEL-3, HT-29 and NCI-H460.  
Compounds 5-7: Except for the hematologic malignancies (HEL92.1.7, Jurkat, U-937), SK-ES-1 and 
LNCaP cells, compounds 5-7 exhibited a distinct increase in cytotoxicity compared to 2-4, showing 
IC50 values in low micro- to nanomolar range and cytocidal effects at concentrations as low as 
1-10 µM at all treated cancer cells. The antiproliferative activity of compounds 5-7 was 
comparable both, in the end-point (cf. Table 5.1) and in the kinetic assays over a period of 5 days 
(Supporting Information, Fig. S5.3 – S5.12). Remarkably, compared to 1, compounds 5-7 were up 
to > 100 times more potent against tumor cells such as SK-MEL3, NCI-H460, HT-29 and MG-63, 
which were refractory against treatment with bendamustine. 
Data on the in vitro cytotoxicity of bendamustine are scarce. In the literature, for myeloma cells 
IC50 values around 100 µM or even higher are reported [22, 23]. A very recent study on several 
hematologic malignancies revealed IC50 values between approximately 10 µM and 250 µM. 
Especially mantle cell lymphoma, Burkitt’s lymphoma and T-cell acute lymphoblastic leukemia 
derived cell lines were relatively sensitive to bendamustine treatment [50]. The IC50 value 
(approximately 50 µM) reported by Hiraoka et al. [50] for Jurkat cells is in good agreement with 
our data. Published plasma levels of 1 after intravenous administration (Cmax = 6 µg/mL (≈ 17 µM) 
[51]; Cmax = 11 µg/mL (≈ 31 µM) [52]) suggest that the chemotherapy with bendamustine must be 
considered ineffective in case of tumor entities showing IC50 values in the two- to three-digit 
micromolar range in vitro.  In this context the up to 100-fold antiproliferative activity of the 
bendamustine esters, in particular 5-7, suggest both, higher efficacy in case of malignancies for 
which the parent compound is approved and a possible extension of the scope of indications.  
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5.3.2 Induction of apoptosis and p53 expression by compounds 1, 2, 4 and 5 
Bendamustine was reported to trigger apoptosis [22]. In search for an explanation of the higher 
antiproliferative activity of the bendamustine esters compared to the parent compound, we 
determined early and late stage of apoptosis by flow cytometry (annexin V/propidium iodide 
staining) after treatment of Jurkat cells with 10 µM of compounds 1, 2, 4 or 5 for 6, 24 and 48 
hours (Fig. 5.3; Fig. S5.13). As becomes obvious from Fig. 5.3, annexin V+/PI+cells, defined as late 
apoptotic/necrotic cells, amounted to approximately 10 % of the total cell population, most 
probably resulting from sample preparation. As expected from the results of the MTT assay, at a 
concentration of 10 µM, bendamustine had no effect compared to the control cells, regardless of 
the period of incubation. After 6 hours, the fraction of early apoptotic cells was less than 1 % 
except for compound 5 (~2.5 %; cf. Supporting Information, Fig. S5.13). Compounds 2 and 4 
showed induction of apoptosis in around 10 % of the cells after 24 hours of incubation. After 48 
hours of incubation, 15 % of the cells were in an early apoptotic state and a considerable fraction 
(20-25 %) was late-apoptotic/necrotic cells. In agreement with the results from the 
chemosensitivity assays, compound 5 was more potent, exhibiting a more rapid onset of action 
and a higher maximal response compared to 1, 2 and 4 regarding induction of apoptosis. 
Approximately 50 % of the cells were either early apoptotic (20 %) or late apoptotic/necrotic (30 
%) after 24 hours. Two days after treatment, only around 15 % of the cells were viable, whereas 
the majority of the cells was late apoptotic (30 %) or necrotic (40 %). 
 
Figure 5.3: Induction of apoptosis in Jurkat cells. 
Results of annexin V/propidium iodide staining, performed after incubating Jurkat cells with 
compounds 1, 2, 4 and 5 at a concentration of 10 µM for different periods. Annexin V+/PI- cells 
were defined as early apoptotic, whereas late apoptotic/necrotic cells were annexin V+/PI+. 
Significances illustrated on top of the columns refer to the overall effect (apoptotic + necrotic 
cells), those depicted in the columns refer to apoptotic cells. After 48 hours, apoptotic and 
necrotic cells were significantly different (p < 0.001) (mean ± SEM, N = 3). One-way ANOVA and 
Bonferroni’s post-test were applied to calculate the significance of the apoptotic fraction and the 
sum of apoptotic and necrotic cells; n.s.: not significant; *: p < 0.05; **: p < 0.01, ***: p < 0.001. 
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Bendamustine was reported to induce the expression of p53 [21, 23, 50]. As the derivatives of 1 
were much more potent against large cell lung and colorectal cancer cells, we investigated the 
induction of p53 expression in NCI-H460 and HT-29 cells after 24 hours of incubation with 
compounds 1, 2, 4 and 5 (Fig. 5.4).  
Figure 5.4: Effect of 1, 2, 4 and 5 on the expression of p53 in NCI-H460 and HT-29 cells. 
Western blot of p53 and histone H2B (loading control) of NCI-H460 (A) and HT-29 (B) cells. A: 
Nuclear extracts of NCI-H460 cells, incubated with different concentrations of 1 (10, 30 and 100 
µM) or 10 µM of 2, 4, or 5 for 24 hours. Nuclear extracts (NE) and whole cell lysates (WCE) of 
untreated cells were used as control (Ctrl). B: Nuclear extracts of HT-29 cells, incubated with 10 
µM of 1, 2, 4, 5 for 24 hours. Untreated cells served as control (Ctrl). 
 
Especially in NCI-H460 cells, p53 expression was significantly induced by the treatment with 10 
µM of compounds 2, 4 and 5, while 5 led to the most pronounced effect. Bendamustine also 
weakly induced the expression of p53, although at a tenfold higher concentration (100 µM). 
Interestingly, p53 was only detectable in nuclear extracts of NCI-H460 cells after treatment, 
whereas HT-29 cells exhibited a high constitutive expression of the tumor suppressor protein. 
Nevertheless, the treatment with compounds 1, 2, 4 and 5 increased the expression of p53 in HT-
29 cells but, similar to NCI-H460 cells, compounds 2, 4 and 5 caused a higher expression level than 
1. Another notable observation was a slight induction of p53 expression in HT-29 cells after 
treatment with 10 µM of 1, since proliferation assays revealed no toxic effect at this 
concentration. It is known from the literature that concentrations of ≥ 80 µM of bendamustine 
are required to produce a significant induction of p53 expression in various tumor cell types [22]. 
Both, the induction of p53 and apoptosis, correlated with the cytotoxic potency of bendamustine 
and derivatives.  
 
5.3.3 Cellular accumulation of bendamustine and derivatives 
Higher cellular uptake of the neutral (2, 3) and basic (4-7) bendamustine esters compared to the 
parent compound could account for the increased potency in terms of antiproliferative activity, 
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induction of apoptosis and p53 expression. Therefore, we performed HPLC analyses to determine 
the amount of cell-associated test compounds 1, 2, 4 and 5 at a concentration of 30 µM after 
10 minutes of incubation. NCI-H460 and HT-29 cells were selected as examples of solid tumors, 
which surprisingly proved to be sensitive against bendamustine esters (Fig. 5.5). The recently 
reported validated HPLC method was applied [34]. To prevent hydrolysis of the nitrogen mustard 
group during sample preparation and analysis, cell lysis and deproteination were performed 
under acidic conditions (1 M perchloric acid, sonication). The esters were proven to be stable over 
the incubation period of 10 minutes in the presence of cells (Supporting Information; Fig. S5.14).  
The cellular association of the internal standard umbelliferone did not significantly differ between 
both cell lines (p > 0.05). The amounts of cell-associated bendamustine (1) were extremely low 
(HT-29: 0.07 ± 0.011 nmol/106 cells; NCI-H460: 0.03 ± 0.001 nmol/106 cells). The ratio of 
cell-associated to the applied concentration of the test compound (accumulation factor) was 1:3 
for NCI-H460 cells and 2:3 for HT-29 cells, indicating an incomplete uptake. In contrast, 
compounds 2, 4 and 5 revealed considerably higher cell-associated amounts, with 5 reaching the 
highest cellular concentrations. A pronounced cellular enrichment of 2, 4 and 5 was particularly 
observed in HT-29 cells. Compounds 2 (2.05 ± 0.39 nmol/106 cells) and 4 (1.59 ± 0.23 nmol/106 
cells) revealed a 20- to 30-fold, and 5 (5.01 ± 0.34 nmol/106 cells) an approximately 70-fold higher 
cellular enrichment than bendamustine. Qualitatively, the cellular accumulation of the 
bendamustine derivatives was comparable in HT-29 and NCI-H460 cells, though at a lower level 
(factor of approximately three) in case of the latter. The amounts of cell-associated 2, 4 and 5 
were 0.28 ± 0.06 nmol/106 cells, 0.59 ± 0.04 nmol/106 cells and 1.89 ± 0.14 nmol/106 cells, 
respectively.  
 
Figure 5.5: Accumulation of 1 and compounds 2, 4 and 5 by HT-29 and NCI-H460 cells. 
Amount (mean ± SEM, N = 3-4) of cell-associated 1, 2, 4 and 5, expressed as nmol/106 cells (left y-
axis) and cellular enrichment (right y-axis) in HT-29 (A) and NCI-H460 (B) cells. A mean cell volume 
of 3 pL was used to calculate accumulation factors. Significance was calculated using one-way 
Anova: n.s.: not significant; *: p < 0.05; **: p < 0.01, ***: p < 0.001.  
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The levels of cellular enrichment correlate very well with the antiproliferative activities, 
underlining a crucial role of the ester moiety depending on the chemical nature, covering a 
neutral group (2) or substructures with different degree of basicity (4 and 5). In particular, the 
contribution of the pyrrolidino group in 5, which is positively charged under assay conditions, 
becomes obvious from the increased cellular accumulation which is paralleled by the 
antiproliferative activity, the induction of apoptosis and p53 expression. The high cellular 
accumulation of 5 and the comparable effects of 5-7 concerning the toxicity suggest an important 
role of the basic substituent and the positive charge for the cellular association and thus for the 
toxicity. Apart from that, the significant difference between HT-29 and NCI-H460 cells might result 
from a different extent of diffusion and transporter-mediated uptake. Therefore, a possible 
contribution of organic cation transporters (OCT) was taken into account [53]. To test this 
hypothesis, functional studies on recombinant OCT1 and OCT3, expressed in HEK293 cells, were 
performed. Additionally, the expression of the respective transporters by the tumor cell types 
selected for cytotoxicity studies was investigated.  
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5.3.4 Effect of bendamustine derivatives on the activities of OCT1 and OCT3 
5.3.4.1 ASP+ uptake by OCT1 and OCT3 expressing HEK293 cells  
Confocal laser scanning microscopy revealed specific uptake of the fluorescent substrate ASP+ by 
organic cation transporter expressing HEK293 cells (Fig. 5.6). OCT1 activity was lower than that of 
OCT3. The activities of both transporters were inhibited by compound 5 and the reference 
inhibitor TPA (Fig. 5.6).  
 
Figure 5.6: Confocal laser scanning microscopy of Cellular ASP+ uptake via OCT1 and OCT3. 
Uptake of fluorescent ASP+ [1 µM] (green) in the absence and presence of compound 5 or TPA 
after 5 minutes of pre-incubation. Nuclei were stained with Draq5 [5 µM] (red). A, B: HEK-Co 
(control) cells, treated with Draq5 (A) or ASP+ plus Draq5 (B). C-E: HEK-OCT1 cells, treated with 
ASP+ plus Draq5 (C), ASP plus Draq5 plus compound 5 [15 µM] (D), or ASP+ plus Draq5 plus TPA 
[200 µM] (E). F-H: HEK-OCT3 cells, treated with ASP+ plus Draq5 (F), ASP+ plus Draq5 plus 
compound 5 [15 µM] (G), or ASP+ plus Draq5 plus TPA [200 µM] (H). 
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5.3.4.2 Determination of the affinities of OCT1 and OCT3 to ASP+ as substrate.  
Flow cytometry was applied to determine Km values (Fig. 5.7). The kinetics of ASP+-uptake and 
thus the increase in fluorescence were linear for both transporters (Fig. 5.7A), allowing the 
determination of initial velocities (v0) at different concentrations (Fig. 5.7B). The affinity to ASP+ 
was not significantly different for OCT1 (Km = 3.1 ± 0.1 µM) and OCT3 (Km = 2.7 ± 0.1 µM). By 
contrast, the maximal uptake rate for ASP+ was significantly higher for 
OCT3 (vmax = 5321 ± 89 MFI/(104 cells · min)) than for OCT1 (vmax = 2808 ± 78 MFI/(104 cells · min); 
p < 0.001). 
 
Figure 5.7: Specific uptake of ASP+ and Michaelis-Menten kinetics determined by flow cytometry.  
A: Time dependency of the specific mean fluorescence intensity (MFI) after incubating HEK-OCT1 
and HEK-OCT3 cells with 1 µM ASP+ (means ± SEM, N = 3). 
B: Concentration dependency of the initial velocity of the specific increase in the mean 
fluorescence intensity (MFI) caused by ASP+-uptake into HEK-OCT1 and HEK-OCT3 cells. HEK cells 
transfected with an empty vector served as control for unspecific uptake (means ± SEM, N = 3). 
 
5.3.4.3 Inhibition of OCT mediated ASP+ uptake by bendamustine derivatives.  
Bendamustine (1), the derivatives 2, 4 and 5 and the standard inhibitor tetrapentyl ammonium 
(TPA) were investigated in the flow cytometric ASP+-uptake assay to determine IC50 values. The 
IC50 values of TPA in HEK-OCT1 (IC50 = 6.04 ± 0.83 µM) and HEK-OCT3 (IC50 = 19.9 ± 2.23) cells were 
consistent with previously published data, obtained in a microtiter assay (OCT1: IC50 = 7.9 µM 
[46], OCT3: IC50 = 28 µM [47]). Whereas compounds 2, 4 and 5 (Fig. 5.8) revealed concentration-
dependent inhibition of both transporters, incomplete inhibition of OCT1 (35 %) and OCT3 (37 %) 
was observed at the highest examined concentration of bendamustine (200 µM). Compounds 2 
and 4 were comparable to TPA at OCT1, whereas 5 was more potent by a factor of approximately 
20 (Table 5.2). By contrast, compounds 2, 4 and 5 were almost equipotent at OCT3 and 
approximately four times more potent than the reference compound TPA (p ≤ 0.05). Several 
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studies conducted in the last years focused on 
the uptake of cytostatic drugs by organic 
cation transporters. Oxaliplatin [54], picoplatin 
[55], imatinib [56], paclitaxel and irinotecan 
[57] were identified as OCT1 substrates and 
oxaliplatin [58], melphalan, irinotecan and 
vincristine [59] as substrates for OCT3. 
Compared to other cytostatic drugs such as 
cisplatin (IC50 value > 100 µM at OCT1 [60]) and 
mitoxantrone (IC50 16 µM at OCT1; 440 µM at 
OCT3 [61]), especially 5 revealed remarkably higher potency at OCT1 (IC50 0.35 ± 0.03 µM). 
Whether compounds 2, 4 and 5 are inhibitors or substrates of OCT1 and OCT3 is a matter of 
question. Supposed that these bendamustine derivatives, in particular the basic ester 5, are 
substrates, accumulation and cytotoxicity should be related to the OCT expression.  
 
 
Figure 5.8: Concentration-dependent inhibition of ASP+-uptake by OCT expressing HEK-cells. 
Inhibition of ASP+-uptake (1 µM) into HEK-OCT1 (A) and HEK-OCT3 (B) cells by TPA, 2, 4 or 5. The 
mean fluorescence intensities were normalized to uninhibited ASP+-uptake (N=3). 
 
5.3.4.4 Expression of OCT1 (SLC22A1) and OCT3 (SLC22A3) by cancer cells.  
Previously, OCT1-mediated uptake of cytostatics in tumor cells was reported for chronic myeloid 
leukemia [56], chronic lymphocytic leukemia [57], and colon carcinoma [54], whereas OCT3 
expression was associated with colorectal [58] and renal cancer [59]. We applied quantitative RT-
PCR for the examination of OCT1 and OCT3 expression in all used cancer cell lines (Fig. 5.9). 
Table 5.2: IC50 (µM) values (± SEM, N=3) of the 
ASP+-uptake inhibition into HEK-OCT1 and 
HEK-OCT3 cells.  
 
Compound OCT1 OCT3 
TPA 6.04 ± 0.83 19.9 ± 2.23 
1 > 200 > 200 
2 11.32 ± 1.93 5.07 ± 1.41 
4 10.05 ± 2.49 5.11 ± 0.02 
5 0.35 ± 0.03 3.41 ± 0.16 
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Whereas OCT1 was weakly expressed in SK-ES1 and SK-MEL3 cells, OCT3 expression was high in 
HT-29 cells, and clear bands were detectable upon analysis of Capan-1 and LNCaP cells. The 
differential expression (Fig. 5.9) does not support the hypothesis that the chemosensivities of the 
investigated cancer cell types (Table 5.1) are primarily determined by OCT-mediated uptake of 
the bendamustine esters.  
 
 
Figure 5.9: Gel electrophoretic analysis of SLC22A1 (encoding human OCT1) and SLC22A3 
(encoding human OCT3) mRNA expression by different human cancer cell types after quantitative 
RT-PCR. Human SLC22A1 mRNA was detected using the primer pair oOCT1-RT.for – oOCT1-RT.rev, 
resulting in a specific band of 319 bp, human SLC22A3 mRNA by the primer pair oOCT3-RT.for – 
oOCT3-RT.rev, resulting in a band of 439 bp. As a positive control, the plasmids pOCT1.31 and 
pOCT3.31 (cDNA) were used as templates of SLC22A1 and SLC22A3, respectively. NTC = non-
template control. Data provided by Prof. Dr. Jörg König. 
 
5.4 Conclusion 
Although the investigated compounds are sufficiently stable to act as antitumor agents on their 
own, it cannot be precluded that the esters are only prodrugs, allowing for increased intracellular 
accumulation of bendamustine. Having the N-Lost moiety in common, alkylating property is a 
characteristic feature of both, the parent compound and the derivatives. In concert with the 
increase in apoptotic processes and elevated p53 expression, the data may be interpreted as a 
hint to a dual mechanism of action, in particular in case of the basic bendamustine esters. 
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5.5 Supporting Information 
 
Figure S5.1: Characterization of HEK293 cells stably expressing human OCT1. A: Immunoblot 
analysis of lysates (20 µg each) of HEK-Co and HEK-OCT1 cells. OCT1 was detected with the 
antiserum KEN (see: Material and Methods). B: Immunolocalization of human OCT1 in HEK-Co 
and HEK-OCT1 cells by confocal microscopy. The OCT1 protein was detected in the plasma 
membrane of transfected HEK-OCT1 cells and no OCT1-specific staining was detectable in HEK-
Co cells. C: Concentration dependent [3H]MPP+ uptake in HEK-Co and HEK-OCT1 cells (incubation 
time: 3 min). D: Time-dependent uptake of [3H]MPP+ (50 µM)  by HEK-Co and HEK-OCT1 cells. In 
both cases OCT1-mediated uptake (squares) of [3H]MPP+ was determined by subtracting uptake 
in HEK-Co cells from the uptake into HEK-OCT1 cells. Data provided by Prof. Dr. Jörg König. 
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Figure S5.2: Concentration-response curves of 1, 2 and 5 against Jurkat (A) and HT-29 (B) cells 
after 96 hours of incubation. T/Ccorr values represent the net proliferation of the treated cells 
referred to the vehicle treated control cells (set to 100%). The obtained data were used for the 
calculation of IC50 values (mean values ± SEM of 2-3 independent experiments with 4 replicates 
per concentration). 
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Figure S5.3: Chemosensitivity of HEL92.1.7 cells against compounds 1 and 3-7. Antiproliferative 
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open 
circles) correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 
replicates per concentration and time point. 
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Figure S5.4: Chemosensitivity of Jurkat cells against compounds 1 and 3-7. Antiproliferative and 
cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open circles) 
correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 replicates 
per concentration and time point. 
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Figure S5.5: Chemosensitivity of U-937 cells against compounds 1 and 3-7. Antiproliferative and 
cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open circles) 
correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 replicates 
per concentration and time point. 
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Figure S5.6: Chemosensitivity of MG-63 cells against compounds 1 and 3-7. Antiproliferative and 
cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open circles) 
correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 replicates 
per concentration and time point. 
104 Chapter V  
 
 
Figure S5.7: Chemosensitivity of SK-ES-1 cells against compounds 1 and 3-7. Antiproliferative 
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open 
circles) correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 
replicates per concentration and time point. 
 Supporting Information 105 
 
 
Figure S5.8: Chemosensitivity of Capan-1 cells against compounds 1 and 3-7. Antiproliferative 
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open 
circles) correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 
replicates per concentration and time point. 
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Figure S5.9: Chemosensitivity of LNCaPcells against compounds 1 and 3-7. Antiproliferative and 
cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open circles) 
correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 replicates 
per concentration and time point. 
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Figure S5.10: Chemosensitivity of NCI-H460 cells against compounds 1 and 3-7. Antiproliferative 
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open 
circles) correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 
replicates per concentration and time point. 
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Figure S5.11: Chemosensitivity of HT-29 cells against compounds 1 and 3-7. Antiproliferative and 
cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open circles) 
correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 replicates 
per concentration and time point. 
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Figure S5.12: Chemosensitivity of SK-MEL-3 cells against compounds 1 and 3-7. Antiproliferative 
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open 
circles) correspond to the right y-axes. Mean values ± SEM of 2-3 independent assays with 8 
replicates per concentration and time point. 
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Figure S5.13: Flow cytometric analysis of Jurkat cells. Cells were treated with 10 µM 1, 2, 4 and 
5 after different periods of incubation (6, 24, 48 hours) by  annexin V-FITC (x-axis) and propidium 
iodide (y-axis) staining. Samples of untreated cells were collected at the same time points and 
served as control (Ctrl). The indicated percentages are related to the total number of collected 
single cells. The different test compounds are arranged horizontally. 
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Figure S5.14: Stability of compounds 1 and 4 in the presence of NCI-H460 cells. Representative 
chromatograms, indicating the stability of compounds 1 and 4 in the presence of NCI-H460 cells 
(IS = internal standard, umbelliferone). Samples were measured immediately before the 
incubation (t = 0 minutes) and after 10 minutes of incubation at 25 °C (t = 10 minutes). The kinetics 
of the hydrolysis of the N-Lost group, yielding 1a or 4a, is the same in case of bendamustine (1) 
and the morpholinoethyl ester 4, respectively. Other decomposition products were not detected. 
The same holds for compounds 2 and 5 upon incubation with cells under the same conditions 
(data not shown). 
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ABC-transporter expression is a crucial mechanism of tumor resistance and was recently also 
associated with cancer initiating cells (CIC). Flow cytometry was applied to detect the expression 
of CIC-markers, ABCB1 and ABCG2 in human brain- and breast cancer cell lines and to examine 
possible correlations between ABC-transporter expression and CICs. Only one of the investigated 
brain tumor cell lines (Daoy) comprised cells expressing CIC-markers which revealed increased 
clonogenicity in vitro.  
For investigations on the correlation between CICs and ABCG2, MCF-7 breast cancer cells were 
treated with topotecan (Topo) to induce ABCG2 expression. Topo treatment led to increased 
resistance against cytostatic drugs, which are substrates of ABCG2. Concurrently, Topo treatment 
induced a reversible decrease in the expression of the CIC-markers CD24 and EpCAM, but did not 
result in increased clonogenicity in vivo. In contrast, Topo treated cells revealed decreased 
tumorigenicity, most probably due to the down-regulation of CD24 and EpCAM. Nevertheless, 
further investigations are necessary to determine whether ABCG2 induction and CD24/EpCAM 
down-regulation are interrelated or independent processes.  
The nitrogen mustard (N-Lost) derivative bendamustine (BM) has been approved as an anticancer 
drug for the treatment of hematopoietic malignancies for decades. Nevertheless, as becomes 
obvious from a series of recent publications and patent applications, there is increasing interest 
in this cytostatic with respect to, for example, improved oral bioavailability of BM by optimized 
formulations. Following a different approach, in this thesis the potential of esters of BM was 
explored, with a focus on representative aminoalkyl esters. Alkyl- and various aminoalkyl (e.g. 2-
morpholinoethyl or 2-pyrrolidinoethyl) esters of BM were investigated for stability in various 
media and cytotoxicity in vitro against a broad panel of human malignancies.  
For this purpose, a fast, selective RP-HPLC method using fluorescence detection was established 
and validated. This method enabled the separation of complex mixtures of analytes and 
degradation products with low limits of quantification and high accuracy and precision. Liquid 
phase extraction with perchloric acid yielded high recovery rates and proved to be applicable to 
the determination of the stability of BM and BM esters in biological material.  
In aqueous solution, the half-life of the N-Lost moiety remained essentially unchanged upon 
esterification of BM. The N-Lost group was significantly more stable in murine plasma, whereas 
the ester bonds were prone to enzymatic cleavage. Interestingly, the nitrogen mustard group was 
even more stable in human than in murine plasma. The stability of the ester bond substantially 
depended on the chemical nature of the substituents at the ester group. Kinetic studies in the 
presence of plasma, butyrylcholine esterase and physostigmine revealed that the basic esters are 
substrates of unspecific choline esterases. While alkyl esters and the mofetil ester had 
significantly longer half-lives in human compared to murine plasma, basic esters, except for the 
branched 1-methyl-2-pyrrolidinoethyl ester, were cleaved rapidly. The discrepancies between the 
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species-dependent stabilities of the BM derivatives can be attributed to lower albumin content 
and higher enzymatic activity in mouse compared to human plasma. 
Surprisingly, cytotoxicity studies revealed that the BM derivatives possess considerably increased 
antiproliferative activity against a panel of human cancer cells, representing not only hematologic 
malignancies but also solid tumors (e.g. malignant melanoma, colorectal carcinoma and lung 
cancer), which are resistant to the parent compound BM. Although the investigated compounds 
are sufficiently stable to act as antitumor agents on their own, it cannot be precluded that the 
esters are prodrugs, allowing for increased intracellular accumulation of BM. Especially, basic 
esters, positively charged under physiological conditions, were up to approximately 100 times 
more effective than BM. This was paralleled by a higher fraction of early apoptotic cancer cells 
and increased expression of p53.   
As HPLC analyses revealed cellular enrichment of the esters with the highest accumulation factor 
in case of the pyrrolidinoethyl ester, transport by organic cation transporters OCT1 and OCT3 was 
taken into account. Although differential interactions of the BM derivatives with these 
transporters were confirmed in vitro, the OCT expression (mRNA level) of the investigated human 
sarcoma and carcinoma cells did not support the hypothesis of an OCT mediated uptake 
contributing to the drastic increase in chemosensitivity. 
The presented approach to increasing cellular access, enhancing antiproliferative activity – also 
against cancer cells refractory to the parent compound - by chemical derivatization might also 
add value to alkylating agents other than bendamustine. 
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RP reverse phase 
RSD relative standard deviation 
RT room temperature 
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SP side population 
SSC side scatter 
t½  half life 
Topo topotecan 
TPA tetrapentyl ammonium 
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